Title of Invention	SUBSTITUTED 1,3-DIARYL-2-PYRIDINE-YL-3-(PYRIDINE-2-YLAMINO)-PROPANOL DERIVATIVES, METHODS FOR THEIR PRODUCTION PHARMACEUTICAL COMPOSITION CONTAINING THE SAME
Abstract	ABSTRACT IN/PCT/2001/00459/CHE "Substituted l,3-diaryl-2-pyridine-2-yl-3-(pyridine-2-ylamino)-propanol derivatives, methods for their production, pharmaceutical compositions containing the same" The invention relates to substituted l,3-diaryl-2-pyridine-2-yl-3-(pyridine-2-ylamino)-propanol derivatives and their pharmaceuticaly acceptable salts and physiologically functional derivatives. The invention describes substituted 1,3-diaryl-2-yl-3-(pyridine-2-ylamino)-propanol derivatives of formula (I), wherein the radicals have the defines meanings, as well as their physiologically acceptable salts, and methods for their production. The compounds are suitable, e.g. as hypolipidemic agents.

Title of Invention

SUBSTITUTED 1,3-DIARYL-2-PYRIDINE-YL-3-(PYRIDINE-2-YLAMINO)-PROPANOL DERIVATIVES, METHODS FOR THEIR PRODUCTION PHARMACEUTICAL COMPOSITION CONTAINING THE SAME

Abstract

ABSTRACT IN/PCT/2001/00459/CHE "Substituted l,3-diaryl-2-pyridine-2-yl-3-(pyridine-2-ylamino)-propanol derivatives, methods for their production, pharmaceutical compositions containing the same" The invention relates to substituted l,3-diaryl-2-pyridine-2-yl-3-(pyridine-2-ylamino)-propanol derivatives and their pharmaceuticaly acceptable salts and physiologically functional derivatives. The invention describes substituted 1,3-diaryl-2-yl-3-(pyridine-2-ylamino)-propanol derivatives of formula (I), wherein the radicals have the defines meanings, as well as their physiologically acceptable salts, and methods for their production. The compounds are suitable, e.g. as hypolipidemic agents.

Full Text	Substituted 1,3-diaryl-2-pyrid-2-yl-3-(pyrid-2-ylamino)propanol derivatives, processes for their preparation, pharmaceuticals comprising these compounds and their use The invention relates to substituted 1,3-diaryl-2-pyridin-2-yl-3-(pyridin-2-yiamino)propanol derivatives and pharmaceutical ly tolerated salts and physiologically functional derivatives thereof. Several classes of active compounds for treatment of adiposity and disturbances in lipid metabolism have already been described: - polymeric adsorbers, such as, for example, cholestyramine - benzodiazepines (WO 93/16055) - bile acid dimers and conjugates (EP 0 489 423) - 4-amino-2-ureido-pyrimidine-5-carboxamides (EP 0 557 879) The invention was based on the object of providing further compounds which display a therapeutically valuable hypolipidemic action. The invention therefore relates to 1,3-diaryl-2-pyridin-2-yl-3-(pyridin-2-ylamino)propanol derivatives of the formula I, in which Zis -NH-(Ci-Cie-alkyl)-(C=0)-; -(C=0)-(Ci-Ci6-alkyl)-(C=0)-; ./r.-rw.nHcLn\A.ir-rw- ■ 12 3 4 A , A , A , A , independently of one another are an amino acid radical, an amino acid radical which is mono- or polysubstituted by amino acid-protective groups; E is -S02-R4, -CO-R4; R is phenyl, thiazolyl, oxazolyl, thienyl, thiophenyf, furanyl, pyridyl, pyrimidyl, it being possible for the rings to be substituted up to 3 times by F, CI, Br, OH, CF3, N02, CN, OCF3, -(Ci-C6)- alkyl, (XCt-CeJ-alkyl, S-(Ci-C6)-alkyl, SO-(Ci-C6)-alkyl, S02-(Ci-C6)-alkyl, (Ci-C6)-alkyl, (C3-C6)-cycloalkyl, COOH, COO(Ci-Ce)alkyl, COO(C3-C6)cycloalkyl, CONH2, CONH(Ci-C6)alkyl, CON[(Ci-C6)alkyl]2, CONH(C3- C6)cycloalkyl, NH2, NH-CO-(Ci-C6)-alkyl, NH-CO-phenyl; R2is H, OH, CH2OH, OMe; R3 is H, F, methyl, OMe; R4 is -(Ci-Cie-alkyI), -(C0-Ci6-alkylene)-R5, -(C=O)-(C0-Ci6- alkylene)-R5, -(C=O)-(C0-C16-alkylene)-NH-R5, -(Ci-C8-alkenylene)-R5, -(Ci-C8-alkynyl), -(Ci-C4-alkylene)-S(O)0 - 2 -R5, -{Ci-C4-alkylene)-0 -R5, -(Ci-C4-alkylene)-NH -R5; R5is -COO-R6, -(C=0)- R6 , -(Ci-C6-alkylene)-R7, -(Ci-C6- alkenylene)-R , {-(Ci-C7)-cycloalkyl, phenyl, naphthyl, thienyl, thiophenyl, furanyl, pyridyl, pyrimidyl, dihydropyrimidine-2,4-dion-6-yl, chromanyl, phthalimidoyl, thiazolyl, it being possible for the rings to be substituted up to 3 times by F, CI, Br, OH, CF3, N02, CN, OCF3, -(Ci-C6)- alkyl, 0-(Ci-C6)-alkyl, S-(Ci-C6)-alkyl, S0-(Ci-C6)-alkyl, S02-(Ci-C6)-alkyl, (Ci-C6)-alkyl, (C3-C6)-cycloalkyl, COOH, COO(Ci -C6)alkyl, COO(C3-C6)cycloalkyl, CONH2, CONHfCrCelalkyl, CON[(Ci-C6)alkyl]2, CONH(C3-C6)cycloalkyl, NH2, NH-CO-(Ci-C6)-alkyl, NH-CO-phenyl, pyridyl; R6 is H,-(Ci-C6)alkyl; R is H, (-(C-\|-C7)-cycloalkyl, phenyl, naphthyl, thienyl, thiophenyl, furanyl, pyridyl, pyrimidyl, dihydropyrimidine-2,4-dion-6-yl, chromanyl, phthalimidoyl, thiazolyl, it being possible for the rings to be substituted up to 3 times by F, CI, Br, OH, CF3, N02, CN, OCF3, -(Ci-C6)-alkyl, 0-(Ci-C6)-alkyl, S- I, q, m, n, 0, p independently of one another are 0 or 1, where l+q+m+n+o+p is greater than or equal to 1; and pharmaceutical^ tolerated salts and physiologically functional derivatives thereof. Preferred compounds of the formula I are those in which one or more radical(s) has or have the following meaning: Z -NH-(Ci-Ci6-alkyl)-(C=0)-, - A , A , A , A , independently of one another, an amino acid radical, an amino acid radical which is mono- or polysubstituted by amino acid-protective groups; E -SO2-R4, -CO-R4; R phenyl, thiazolyl, oxazolyl, thienyl, thiophenyl, furanyl, pyridyl, pyrimidyl, it being possible for the rings to be substituted up to 3 times by F, CI, Br, OH, CF3, N02, CN, OCF3, -(Ci-C6)- alkyl, 0-(Ci-C6)-alkyl, S-(Ci-Ce)-alkyl, S0-(Ci-C6)-alkyl, S02-(Ci-C6)-alkyl, (Ci-C6)-alkyl, (C3-C6)-cycloalkyl, COOH, COO(d-C6)alkyl, COO(C3-C6)cycloalkyl, CONH2, CONH(Ci-C6)alkyl, CON[(Ci-C6)alkyl]2, CONH(C3-C6)-cycloalkyl, NH2, NH-CO-(d-C6)-alkyl, NH-CO-phenyl,; R2 H, OH, CH2OH, OMe; R3 H, F, methyl, OMe; R4 -(Ci-Cie-alkyI), - alkylene)-R5, -(C=O)-(C0-C16-a!kylene)-NH-R5, -(Ci-C8-alkenylene)-R5, -{Ci-C8-alkynyl), -(Ci-C4-alkylene)-S(0)o - 2 -R5, -(d-C4-alkylene)-0 -R5, -(Ci-C4-alkylene)-NH -R5; R5 -COO-R6, -(C=0)- R6 , -(Ci-C6-alkylene)-R7, -(Ci-C6- alkenylene)-R , -(Ci-C7)-cycloalkyl, phenyl, naphthyl, thienyl, thiophenyl, furanyl, pyridyl, pyrimidyl, dihydropyrimidine- 2,4-dion-6-yl, chromanyl, phthalimidoyl, thiazolyl, it being possible for the rings to be substituted up to 3 times by F, CI, Br, OH, CF3, N02, CN, OCF3, -(Ci-C6)-alkyl, 0-(Ci-C6)- alkyl, S-(Ci-C6)-alkyl, SO-(Ci-C6)-alkyl, S02-(Ci-C6)-alkyl, (Ci-C6)-alkyl, (C3-C6)-cycloalkyl, COOH, COO(Ci-C6)alkyl, COO(C3-C6)cycloalkyl, CONH2, CONH(C-\|-C6)alkyl, CON[(Ci-C6)aikyl]2, CONH(C3-C6)cycloalkyl, NH2, NH-CO-(Ci-C6)-alkyl, NH-CO-phenyl, pyridyl; R6 H,-(d-C^alkyl; R H, (-(Ci-C7)-cycloalkyl, phenyl, naphthyl, thienyl, thiophenyl, furanyl, pyridyl, pyrimidyl, dihydropyrimidine-2,4-dion-6-yl, chromanyl, phthalimidoyl, thiazolyl, it being possible for the rings to be substituted up to 3 times by F, CI, Br, OH, CF3, N02, CN, OCF3, -(d-CeJ-alkyl, 0-(CrC6)-alkyl, S-(Ci-C6)-alkyl, SO-td-CeJ-alky], S02-{Ci-C6)-alkyl, (d-C6)-alkyl, (C3-C6)-cycloalkyl, COOH, COO(d-C6)alkyl, COO(C3-C6)cycloalkyl, CONH2, CONH(d-C6)alkyl, CON[(CT C6)alkyl]2, CONH(C3-C6)cycloalkyl, NH2, NH-CO-(Ci-C6)-alkyl, NH-CO-phenyl; I 0 or 1; m, n 0; o 1; p 0 or 1; q 0or1; and pharmaceutical^ tolerated salts and physiologically functional derivatives thereof. Particularly preferred compounds of the formula I are those in which one or more radical(s) has or have the following meaning: 2 -NH-(Ci-Ci2-alkyl)-(C=0)-, -(C=OHCi-Ci2-alkyl)-(C=0)-, -(C=0)-phenyl-(C=0)-; 12 3 4 A , A , A , A , independently of one another, an amino acid radical, an amino acid radical which is mono- or polysubstituted by amino acid-protective groups; E -S02-R4, -C0-R4; R phenyl, thiazolyl, oxazolyl, it being possible for the rings to be substituted up to 3 times by -(Ci-CeValkyl; R2 H, OH, CH2OH, OMe; R3 H, F, methyl, OMe; R4 -(Ci-Cie-alkyI). -(C0-Ci6-alkyiene)-R5, -(C=0)-(Co-Ci6- alkylene)-R5, -(C=OHC0-Ci6-alkylene)-NH-R5, -(Ci-C8-alkenylene)-R , -(C-i-Cs-alkynyl), -(Ci-C4-alkylene)-S(0)o - 2 -R5, -(Ci-C4-alkylene)-0 -R5, -(Ci-C4-alkylene)-NH -R5; R5 -COO-R6, - thienyl, thiophenyl, furanyl, pyridyl, pyrimidyl, dihydropyrimidine-2,4-dion-6-yl, chromanyl, phthalimidoyl, thiazolyl, it being possible for the rings to be substituted up to twice by F, CI, Br, OH, CF3, N02, CN, OCF3, -(Ci-C6)-alkyl, 0-(Ci -C6)-alkyl, COOH, COO(Ci -C6)alkyl, CONH2, CONH(CrC6)alkyl, CON[(Ci-C6)alkyl]2, CONH(C3- C6)cycloalkyl, NH2, NH-CO-(Ci-C6)-alkyl, NH-CO-phenyl, pyridyl; R6 H.-(Ci-Ce)alkyl; I, m, n 0; o 1; p 0 or 1; q 0 or 1; and pharmaceutically tolerated salts thereof. The term alkyl is understood as meaning straight-chain or branched hydrocarbon chains. By the term amino acids or amino acid radicals is meant, for example, the stereoisomeric forms, i.e. D- or L-forms, of the following compounds: alanine glycine proline cysteine histidine glutamine aspartic acid isoleucine arginine glutamic acid lysine serine phenylalanine leucine threonine tryptophan methionine valine tyrosine asparagine 2-aminoadipic acid 2-aminoisobutyric acid 3-aminoadipic acid 3-aminoisobutyric acid beta-alanine 2-aminopimelic acid 2-aminobutyric acid 2,4-diaminobutyric acid 4-aminobutyric acid desmosine piperidic acid 2,2-diaminopimelic acid 6-aminocaproic acid 2,3-diaminopropionic acid 2-aminoheptanoic acid N-ethylglycine 2-(2-thienyl)-glycine 3-(2-thienyl)-alanine penicillamine sarcosine N-ethylasparagine N-methylisoleucine hydroxylysine 6-N-methyllysine allo-hydroxy lysine N-methylvaline 3-hydroxyproline norvaline 4-hydroxyproline norleucine isodesmosine ornithine allo-isoleucine 3-(2-naphthyl)alanine azaglycine N-cyclohexylglycine 2,4-diaminobutyric acid The abbreviated spelling of the amino acids is in accordance with the generally customary spelling (cf. Schroder, Liibke, The Peptides, Volume I, New York 1965, pages XXII-XXIII; Houben-Weyl, Methoden der Organischen Chemie [Methods of organic chemistry], Volume XV/1 and 2, Stuttgart 1974). The amino acid pGlu represents pyroglutamyl, Nal represents 3-(2-naphthyl)alanine, Azagly-Nhfe represents a compound of the formula NH2-NH-CONH2 and D-Asp represents the D-form of aspartic acid. Peptides are acid amides in their chemical nature and dissociate into amino acids on hydrolysis. The invention furthermore relates to processes for the preparation of compounds of the formula I which comprise the following reaction equations (Equation 1 to 6). The compounds of the formula I according to the invention are prepared starting from compounds of the formulae VI or VII in stages from the free amino group or by coupling of segments by the general methods of peptide chemistry (Houben-Weyl, Methoden der Organischen Chemie, Volume 15/1,2). The peptide couplings can be carried out, for example, with TOTU (for the literature see: G. Breipohl, W. Kbnig EP 0460446; W. Kbnig, G. Breipohl, P. Pokorny, M. Birkner in E. Giralt and D. Andreu (Eds.) Peptides 1990, Escom, Leyden, 1991, 143-145) by the method of mixed anhydrides, via active esters, azides or by the carbodiimide method, in particular with the addition of substances which accelerate the reaction and prevent racemization, such as, for example, 1-hydroxybenzotriazole, N-hydroxysuccinimide, 3-hydroxy-4-oxo-3,4-dihydro-1,2,3-benzotriazine, N-hydroxy-5-norbornene-2,3-dicarboximide, and furthermore using active derivatives of 1-hydroxybenzotriazole or anhydrides of phosphoric, phosphonic and phosphinic acids, at a reaction temperature of between -10°C and the boiling point of the solvent, preferably between -5°C and 40°C. Suitable solvents for this are dimethylformamide, dimethylacetamide, N-methylpyrrolidone or dimethyl sulfoxide. If the solubility of the components allows, solvents such as methylene chloride, chloroform or tetrahydrofuran or mixtures of the solvents mentioned can also be employed. The methods mentioned are described, for example, in Meinhofer-Gross: "The Peptides" Academic Press, Volume I, (1979). If necessary to prevent side reactions or for the synthesis of specific peptides, the functional groups in the side chain of amino acids are additionally protected by suitable protective groups (see, for example, T.W. Greene, "Protective Groups in Organic Synthesis"), Arg(BOC)2, Arg(Tos), Arg(Mts), Arg(Mtr), Arg(PMV), Asp(OBzl), Asp(OBut), Cys(4-MeBzl), Cys(Acm), Cys(SBut), Glu(OBzl), Glu(OBut), His(Tos), His(Fmoc), His(Dnp), His(Trt), Lys(CI-Z), Lys(Boc), Met(O), Ser(Bzl), Ser(But), Thr(Bzl), Thr(But), Trp(Mts), Trp(CHO), Tyr(Br-Z), Tyr(Bzl) or Tyr(But) primarily being employed. The benzyloxycarbonyl (Z) radical, which can be split off by catalytic hydrogenation, the 2-(3,5-dimethyloxyphenyl)propyl(2)oxycarbonyl (Ddz) or trityl (Trt) radical, which can be split off by weak acids, and the 9-fluorenyl-methyloxycarbonyl (Fmoc) radical, which can be split off by secondary amines, are preferably used as the amino-protective groups. The SH group of cysteine can be blocked by a number of protective groups. The trityl (Trt) radical and the S-tert-butyl (StBu) radical are preferred here. The trityl radical can be split off by iodine oxidation with formation of the cystine compounds, or by reducing acid cleavage to give the cysteine compounds (Uebigs Ann. Chem. 1979, 227-247). On the other hand, the S-tert-butyl radical is best split off reductively with tributylphosphine (Aust. J. Chem. 19 (1966) 2355-2360). OH and COOH functions in the side chains are best protected by the tert-butyl (tBu) radical, which can be split off under acid conditions (see also: Meienhofer-Gross: "The Peptides", Volume 3). The compounds of the formulae VI and VII are prepared as follows: Compounds of type IV are obtained by reacting o-, m- or p-substituted imines of type II with the ketone III. The reaction can be carried out, for example, by mixing the two compounds in bulk, without a solvent, and subsequently heating the mixture, or in a suitable solvent, such as ethanol, tetrahydrofuran (THF), toluene, diglyme or tetradecane, at temperatures of 20°Cto150°C. The keto compounds of type IV are reduced with NaBhU or another suitable reducing agent in a suitable solvent, such as, for example, methanol, THF or THF/water, at temperatures between -30°C and + 40°C to give hydroxy compounds of type V. Two isomer mixtures (racemates) are usually obtained as the main products in the reduction. The different racemates can be separated from one another by fractional crystallization or by silica gel chromatography. The nitro group in compounds of type V can be reduced by known processes, such as, for example, catalytic hydrogenation with Pd or Pd-on-charcoal and H2 in methanol. The racemic compounds of type VI thus obtained can be separated further into their enantiomers. The racemate splitting of VI into enantiomers of type VII can be carried out by chromatography over chiral column material or by processes which are known from the literature, using optically active auxiliary reagents (cf. J. Org. Chem. 44, 1979, 4891). Preparation of the compounds of the formula I according to the invention starting from compounds of type VI or VII. Compounds of the formula VI or VII are reacted with derivatives of aminoalkanecarboxylic acids. Peptide coupling processes are employed here. The aminoalkanecarboxylic acids, for example glycine, IB-alanine or co-ami no undecanoic acid, are protected with Fmoc groups, and corresponding nitro- or azidocarboxylic acids, for example, can also be used. After the protective group has been split off in a second step, or correspondingly after reduction of the azido or nitro group, compounds of the formula VIII are obtained. Compounds of the formulae VI, VII or VIII can be reacted with amino-protected, for example Fmoc-protected amino acids by peptide coupling processes, and the side chains can be protected with suitable orthogonal protective groups or unprotected. After the coupling reaction, the protective group of the amino function is split off, in the case of Fmoc, for example, with piperidine in DMF. The compounds of type IX obtained therefrom can be reacted in one to three further reaction sequences - amino acid coupling, splitting off of the amino-protective group - to give compounds of the formula X. The protective groups of the side chains of the amino acids A to A , which number up to four, can be split off individually after each reaction sequence or together after all the coupling reactions, or all or some of them can also remain on the compounds X according to the invention. Process B The free amino functions of compounds of the formulae VI, VII, VIII, IX or X are reacted with carboxylic acids, also by customary amide formation methods. Functional groups of the starting compounds which can lead to side reactions must be present in protected form, and can be split off after the reaction with the carboxylic acid, if necessary. The compounds according to the invention of type XI are obtained therefrom. Analogously to process B, the sulfonamide derivatives XII are obtained from the compounds of the formulae VI to IX. For the preparation, the amino functions of the starting compounds can be reacted, for example, with sulfonic acid chlorides in the presence of an auxiliary base in a suitable solvent. Compounds of type XIII can be obtained by reaction of dicarboxylic acid monoalkyl esters with compounds of type VI or VII, X representing an alkyl or a phenyl radical, in accordance with the claims. The reaction is carried out by customary peptide coupling processes. The alkyl ester function is then hydrolyzed to the carboxylic acid in order to obtain compounds of the formula XIV. The compounds XIV can also be obtained directly from the amines of type VI or VII by reaction with dicarboxylic acid anhydrides, for example succinic anhydride, in the presence of a base. If the carboxylic acid function of the compounds XIV is reacted with amino acid alkyl esters which a protective group may carry in the side chain, compounds of the formula XV are obtained. The compounds of the formula XVI are in turn prepared therefrom by hydrolysis of the alkyl ester function. Processes A - D can also be modified in the same sense such that the compounds according to the reaction may be prepared by reactions on a solid phase. This is shown in process E by a general example. Process E The compound of the formula V is coupled to a modified polystyrene resin. For this, the carboxyl group of Carboxy-Tentagel (Rapp, Tubingen) is reacted with the OH function of the compound VI by esterification methods, for example DCC or DMAP. The nitro group of the compound XVII thus obtained is converted into the amino function by suitable methods, for example SuCfe reduction processes. On derivative XVIII, which is bonded to the solid phase, the side chain (E)7-(A )p-(A )0-(A )n-(A )m-(Z)e is built up to the desired length analogously to the peptide coupling processes already described. In the last step, the compounds of the formula I according to the invention are split off from the solid phase by hydrolysis of the ester group under basic conditions. The radicals described as protective groups of amino acid side chains in the processes described can remain in the compounds according to the invention or can be split off by known methods (see T.W. Greene "Protective Groups in Organic Synthesis"). The compounds of the formula I thus obtained can optionally be converted into their pharmaceutical^ tolerated salt or physiologically functional derivative. Because of their higher solubility in water compared with the starting or base compounds, pharmaceutically tolerated salts are particularly suitable for medical uses. These salts must have a pharmaceutically tolerated anion or cation. Suitable pharmaceutically tolerated acid addition salts of the compounds according to the invention are salts of inorganic acids, such as hydrochloric acid or hydrobromic, phosphoric, metaphosphoric, nitric, sulfonic and sulfuric acid, and of organic acids, such as, for example, acetic acid or benzenesulfonic, benzoic, citric, ethanesulfonic, fumaric, gluconic, glycolic, isethionic, lactic, lactobionic, maleic, malic, methanesulfonic, succinic, p-toluenesulfonic, tartaric and trifluoroacetic acid. For medical purposes, the chlorine salt is particularly preferably used. Suitable pharmaceutically tolerated basic salts are ammonium salts, alkali metal salts (such as sodium and potassium salts) and alkaline earth metal salts (such as magnesium and calcium salts). Salts with an anion which is not pharmaceutically tolerated are also included in the scope of the invention as beneficial intermediate products for the preparation or purification of pharmaceutically tolerated salts and/or for use in non-therapeutic, for example in vitro applications. The term "physiologically functional derivative" used here designates any physiologically tolerated derivative of a compound according to the invention, for example an ester, which, when administered to a mammal, such as, for example, humans, is capable of forming (directly or indirectly), such a compound or an active metabolite. Prodrugs of the compounds according to the invention are another aspect of this invention. Such prodrugs can be metabolized in vivo to give a compound according to the invention. These prodrugs may or may not be active themselves. The compounds according to the invention can also exist in various polymorphous forms, for example as amorphous and crystalline polymorphous forms. All the polymorphous forms of the compounds according to the invention are included in the scope of the invention and are a further aspect of the invention. All references to "compound(s) according to formula (I)" in the following text relate to compound(s) of the formula (I) as described above and their salts, solvates and physiologically functional derivatives as described herein. The amount of a compound according to formula (I) which is necessary to achieve the desired biological effect depends on a number of factors, for example the specific compound chosen, the intended use, the mode of administration and the clinical condition of the patient. In general, the daily dose is in the range from 0.3 mg to 100 mg, {typically from 3 mg to 50 mg) per day per kilogram of bodyweight, for example 3-10 mg/kg/day. An intravenous dose can be, for example, in the range from 0.3 mg to 1.0 mg/kg, which can suitably be administered as an infusion of 10 ng to 100 ng per kilogram per minute. Suitable infusion solutions for this purpose can comprise, for example, from 0.1 ng to 10 mg, typically from 1 ng to 10 mg per milliliter. Individual doses can comprise, for example, from 1 mg to 10 g of the active compound. Thus, ampoules for injections can contain, for example, from 1 mg to 100 mg, and individual dose formulations for oral administration, such as, for example, tablets or capsules, can contain, for example, from 1.0 to 1000 mg, typically from 10 to 600 mg. In the case of pharmaceutical^ tolerated salts, the abovementioned weight data relate to the weight of the benzothiazepine ion derived from the salt. For prophylaxis or treatment of the abovementioned conditions, the compounds according to formula (I) can be used themselves as the compound, but they are preferably present together with a tolerated excipient in the form of a pharmaceutical composition. The excipient must of course be tolerated in the sense that it is compatible with the other constituents of the composition and does not harm the health of the patient. The excipient can be a solid or a liquid or both and is preferably formulated with the compound as an individual dose, for example as a tablet, which can comprise from 0.05% to 95% by weight of the active compound. Further pharmaceutically active substances can also be present, including further compounds according to formula (I). The pharmaceutical compositions according to the invention can be prepared by one of the known pharmaceutical methods, which substantially comprise mixing the constituents with pharmacologically tolerated excipients and/or auxiliaries. Pharmaceutical compositions according to the invention are those which are suitable for oral, rectal, topical, peroral (for example sublingual) and parenteral (for example subcutaneous, intramuscular, intradermal or intravenous) administration, although the most suitable mode of administration in each individual case depends on the nature and severity of the condition to be treated and on the nature of the particular compound according to formula (I) used. Coated formulations and coated sustained-release formulations are also included in the scope of the invention. Formulations which are resistant to acid and gastric juice are preferred. Suitable coatings which are resistant to gastric juice include cellulose acetate phthalate, polyvinyl acetate phthalate, hydroxyp ropy I methyl-cellulose phthalate and anionic polymers of methacrylic acid and methyl methacrylate. Suitable pharmaceutical compounds for oral administration can be present in separate units, such as, for example, capsules, cachets, sucking tablets or tablets, each of which comprises a certain amount of the compound according to formula (I); as powders or granules; as a solution or suspension in an aqueous or non-aqueous liquid; or as an oil-in-water or water-in-oil emulsion. As already mentioned, these compositions can be prepared by any suitable pharmaceutical method which comprises a step in which the active compound and the excipient (which can consist of one or more additional constituents) are brought into contact. The compositions are in general prepared by uniform and homogeneous mixing of the active compound with a liquid and/or finely divided solid excipient, after which the product is shaped, if necessary. Thus, for example, a tablet can be prepared by pressing or shaping a powder or granules of the compound, optionally with one or more additional constituents. Pressed tablets can be prepared by tableting the compound in a free-flowing form, such as, for example, a powder or granules, optionally mixed with a binder, lubricant, inert diluent and/or one (or more) surface-active/dispersing agents, in a suitable machine. Shaped tablets can be prepared by shaping the pulverulent compound, which has been moistened with an inert liquid diluent, in a suitable machine. Pharmaceutical compositions which are suitable for peroral (sublingual) administration include sucking tablets which comprise a compound according to formula (I) with a flavoring substance, usually sucrose, and gum arabic or tragacanth, and pastilles, which comprise the compound in an inert base, such as gelatin and glycerol, or sucrose and gum arabic. Suitable pharmaceutical compositions for parenteral administration include, preferably, sterile aqueous formulatlions of a compound according to formula (I), which are preferably isotonic with the blood of the intended recipient. These formulations are preferably administered intravenously, although the administration can also take place subcutaneously, intramuscularly or intradermally as an injection. These formulations can preferably be prepared by mixing the compound with water and rendering the resulting solution sterile and isotonic with blood. Injectable compositions according to the invention in general comprise 0.1 to 5% by weight of the active compound. Suitable pharmaceutical compositions for rectal administration are preferably in the form of individual-dose suppositories. These can be prepared by mixing a compound according to formula (I) with one or more conventional solid excipients, for example cacao butter, and introducing the mixture formed into a mold. Suitable pharmaceutical compositions for topical use on the skin are preferably in the form of an ointment, cream, lotion, paste, spray, aerosol or oil. Vaseline, lanolin, polyethylene glycols, alcohols and combinations of two or more of these substances can be used as excipients. The active compound is in general present in a concentration of 0.1 to 15% by weight of the composition, for example 0.5 to 2%. Transdermal administration is also possible. Suitable pharmaceutical compositions for transdermal applications can be in the form of individual 3atches which are suitable for long-term close contact with the epidermis of the patient. Such patches suitably comprise the active compound in an optionally buffered aqueous solution, dissolved and/or dispersed in an adhesion promoter or dispersed in a polymer. A suitable active compound concentration is about 1% to 35%, preferably about 3% to 15%. As a particular possibility, the active compound can be released by electric transportation or iontophoresis, as described, for example, in Pharmaceutical Research, 2(6): 318 (1986). The invention furthermore relates both to isomer mixtures of the formula I and to the pure enantiomers of the formula I. The compounds of the formula I and pharmaceutical^ tolerated salts and physiologically functional derivatives thereof are ideal pharmaceuticals for treatment of disturbances in lipid metabolism, in particular hyperlipidemia. The compounds of the formula I are also suitable for influencing the serum cholesterol level and for prevention and treatment of arteriosclerotic symptoms. The following findings demonstrate the pharmacological activity of the compounds according to the invention. Biological testing of the compounds according to the invention was carried out by determining the inhibition of [ H]-taurocholate uptake in brush border membrane vesicles of the ileum of rabbits. The inhibition test was carried out as follows: 1. Preparation of brush border membrane vesicles from the ileum of rabbits Brush border membrane vesicles from the intestinal cells of the small 2+ intestine were prepared by the so-called Mg precipitation method. Male New Zealand rabbits (2 to 2.5 kg bodyweight) were sacrificed by ® intravenous injection of 0.5 ml T61 , an aqueous solution of 2.5 mg tetracaine HCI, 100 m embutramide and 25 mg mebezonium iodide. The small intestine was removed and rinsed with ice-cold physiological saline solution. The terminal 7/10 of the small intestine (measured in the oral-rectal direction, i.e. the terminal ileum, which contains the active Na -dependent bile acid transportation system) was used for preparation of the brush border membrane vesicles. The intestines were frozen in plastic bags under nitrogen at -80°C. For preparation of the membrane vesicles, the frozen intestines were thawed at 30°C in a water-bath. The mucosa was scraped off and suspended in 60 ml of ice-cold 12 mM Tris/HCI buffer 2+ addition of Mg and precipitate, with the exception of the brush border membranes. After centrifugation at 3000 x g (5000 rpm, SS-34 rotor) for 15 minutes, the precipitate was discarded and the supernatant, which contains the brush border membranes, was centrifuged at 48000 x g (20000 rpm, SS-34 rotor) for 30 minutes. The supernatant was discarded, and the precipitate was rehomogenized in 60 ml of 12 mM Tris/HCI buffer (pH 7.1)/60mM mannitol, 5 mM EGTA with a Potter Elvejhem homogenizer (Braun, Melsungen, 900 rpm, 10 strokes). After addition of 0.1 ml of 1 M MgCl2 solution and an incubation time of 15 minutes at 0°C, centrifugation was again carried out at 3000 x g for 15 minutes. The supernatant was then centrifuged again at 48000 x g (20000 rpm, SS-34 rotor) for 30 minutes. The precipitate was taken up in 30 ml of 10 mM Tris/Hepes buffer (pH 7.4)/300 mM mannitol and resuspended homogeneously by 20 strokes in a Potter Elvejhem homogenizer at 1000 rpm. After centrifugation at 48000 x g (20000 rpm, SS-34 rotor) for 30 minutes, the precipitate was taken up in 0.5 to 2 ml of Tris/Hepes buffer (pH 7.4)/280 mM mannitol (final concentration 20 mg/ml) and resuspended with the aid of a Tuberculin syringe with a 27-gauge needle. The vesicles were either used for transportation investigations directly after preparation or stored at -196°C in 4 mg portions in liquid nitrogen. 2. Inhibition of the Na+-dependent [ H]taurocholate uptake in brush border membrane vesicles of the ileum The uptake of substrates in the brush border membrane vesicles described above was determined by means of the so-called membrane filtration technique. 10^1 of the vesicle suspension (100 /jg of protein) were pipetted as drops onto the wall of a polystyrene incubation tube (11 x 70 mm) which contained the incubation medium with the corresponding ligands (90 //I). The incubation medium comprised 0.75 /J\ = 0.75 juCi [ H(G)]-taurocholate (specific activity: 2.1 Ci/mmol)/0.5 /J\ of 10 mM taurocholate/8.75/W of sodium transportation buffer (10 mM Tris/Hepes (pH 7.4)/100mM mannitol/100mM NaCI) (Na-T-P) or 8.75//I of potassium transportation buffer (10 mM Tris/Hepes (pH 7.4)/100 mM mannitol/100 mM KCI) (K-T-P) and 80 fj\ of the inhibitor solution in question, dissolved in Na-T buffer or K-T-buffer, depending on the experiment. The incubation medium was filtered through a polyvinylidenefluoride membrane filter (SYHV LO 4NS, 0.45 fjm, 4 mm 0, Millipore, Eschborn, Germany). The transportation measurement was started by mixing the vesicles with the incubation medium. The concentration of taurocholate in the incubation batch was 50 pM. After the desired incubation time (usually 1 minute), the transportation was stopped by addition of 1 ml of ice-cold stopping solution (10 mM Tris/Hepes (pH 7.4)/150mM KCI). The mixture formed was immediately filtered with suction under a vacuum of 25 to 35 mbar over a membrane filter of cellulose nitrate (ME 25, 0.45 ym, 25 mm diameter, Schleicher & Schuell, Dassell, Germany). The filter was rinsed with 5 ml of ice-cold stopping solution. To measure the uptake of the radioactively labeled taurocholate, the membrane filter was dissolved with 4 ml of the scintillator Quickszint 361 (Zinsser Analytik GmbH, Frankfurt, Germany) and the radioactivity was measured by liquid scintillation measurement in a TriCarb 2500 measuring apparatus (Canberra Packard GmbH, Frankfurt, Germany). The values measured were obtained as dpm (decompositions per minute) after calibration of the apparatus with the aid of standard samples and after correction for any chemiluminescence present. The control values were each determined in Na-T-P and K-T-P. The difference between the uptake in Na-T-P and K-T-P gave the Na -dependent transportation content. That concentration of inhibitor at which the Na -dependent transporation content was inhibited by 50% - based on the control - is designated the IC50 Na+. The pharmacological data comprise a test series in which the interaction of the compounds according to the invention with the intestinal bile acid transportation system in the terminal small intestine was investigated. The results are summarized in Table 1. 3 Table 1 shows measurement values of the inhibition of the [ H]- taurocholate uptake in brush border membrane vesicles of the ileum of rabbits. The quotients of the ICsoNa values of the reference substance as taurochenodeoxycholate (TCDC) and of the particular test substance are stated. 366 ml of 15% strength n-butyllithium in n-hexane were added dropwise to 50 g (0.54 mol) of picoline in 770 ml of tetrahydrofuran at -55°C. The mixture was warmed to room temperature and cooled again to -55°C. 77 g of N,N-dimethylbenzamide (0.52 mol) in 570 ml of tetrahydrofuran were slowly added dropwise, and the mixture was then warmed to room temperature and stirred for a further hour. After addition of 550 ml of 1N hydrochloric acid, the mixture was extracted with ethyl acetate (3x) and the organic phases were dried with MgS04 and evaporated. Distillation of the residue gave 47.5 g (47%) of the product. Boiling point 134-136°C/0.28mbar. 20.0 g (0.13 mol) of o-nitrobenzaldehyde, 12.5 g (0.13 mol) of 2-aminopyridine and 0.3 g of p-toluenesulfonic acid were heated under reflux in 150 ml of toluene for 2.5 hours, using a water separator. The solution was cooled and the precipitate formed was filtered off with suction and dried. Yield: 18.1 g (60%) of product Melting point: 93-95°C C12H9N3O2 (227) MS (FAB) 228 M + H+ 12.0 g (61 mmol) of the ketone from Example 1 a and 15.0 g (66 mmol) of the imine from Example 1 b were heated on a steam bath for 45 minutes. The reaction mixture was dissolved in ethanol, with heating. After cooling, the precipitate was filtered off with suction and recrystallized from ethanol. Yield: 11.8 g (46%) of product C25H20N4O3 (424.2) MS (FAB) 425 M + H+ 8.0 g (18.8 mmol) of the keto compound from Example 1 c w re dissolved in 300 ml of tetrahydrofuran/water 10:1, 4.67 g of sodium bore lydride were added and the mixture was stirred at room temperature for ! hours. The solution was then evaporated, 100 ml of 2N hydrochloric acic were added to the residue and the mixture was heated on a steam bath ur til everything had dissolved. After cooling, the mixture was rendered basic v\ th 4N NaOH solution and extracted with ethyl acetate (2x). The organic ihases were dried with MgS04 and evaporated. The residue was chromato iraphed over silica gel (heptane/ethyl acetate 1:1). Two racemic comf ounds were obtained as the product. 1 st fraction: 3.9 g (48%) of non-polar racemate (Example 1 d/1) C25H22N4O3 (426.2) MS (FAB) 427 M + H+ 2nd fraction: 2.5 g (31%) of polar racemate (Example 1 d/2) C25H22N4O3 (426.2) MS (FAB) 427 M + H+ 2.5 g (5.86 mmol) of the non-polar racemate from Example 1 d/1 were dissolved in 300 ml of methanol, about 20 mg of Pd/C 10% were added and hydrogenation was carried out at room temperature under an H2 atmosphere. The catalyst was filtered off and the solution was evaporated. The residue was chromatographed over silica gel (n-heptane/ethyl acetate 7:13). Yield: 1.9 g (82%) of product C25H24N4O (396.22) MS (FAB) 397 M + H+ 100 mg of the racemic compound from Example 1 e was separated into the enantiomers by preparative HPLC. The separation was carried out over a CSP-Chiralpak column (Daicel, Dusseldorf) with n-hexane/ethanol 4:1. 40 mg of the (-)-enantiomer (Example 1 f/1) were obtained as the 1st fraction and 40 mg of the (+)-enantiomer (Example 1 f/2) were obtained as the 2nd fraction. 4.0 g (10.1 mmol) of the amino compound from Example 1e (non-polar racemate), 4.85 g (10.3 mmol) of N-Fmoc-D-l_ys(BOC)OH, 4.0 g (12.2 mmol) of TOTU and 2.7 ml of triethylamine were dissolved in 300 ml of dimethylformamide and the mixture was stirred at room temperature for 2 hours. The reaction mixture was poured onto water and extracted with ethyl acetate (2 x). The organic phases were dried (MgS04) and evaporated. The residue was dissolved in 150 ml of dimethyl- formamide/piperidine 2:1, for splitting off the Fmoc group, and the solution was stirred at room temperature for 1 hour. It was poured onto water and extracted with ethyl acetate (3 x). The organic phases were dried (MgS04) and evaporated. Chromatography over silica gel (methylene chloride/methanol 9:1) gave 4.0 g (63.5%) of the product C36H44N6O4 (624.3) MS (FAB) 625 M + H+ 4.74 g (43%) of the product were obtained from 8.0 g of the compound from Example 1 g (12.8 mmol) and 6.4 g (13.7 mmol) of N-Fmoc-D- Lys(BOC)OH by the process described under 1 g. C47H64N8O7 (852.5) MS (FAB) 853.5 M + H+ 2.5 g (6.31 mmol) of the amino compound from Example 1 e (non-polar racemate), 2.2 g (6.52 mmol) of Fmoc-L-proline, 2.5 g (7.62 mmol) of TOTU and 1.7 ml of triethylamine were dissolved in 100 ml of dimethyl-formamide and the solution was stirred at room temperature for 3 hours. The reaction mixture was evaporated to half, water was added and the mixture was extracted with ethyl acetate (3 x). The organic phases were dried over MgS04 and evaporated. After chromatography over silica gel (ethyl acetate/n-heptane 7:3), 3.85 g (85%) of product were obtained. This Fmoc-protected intermediate product (3.6 g) was dissolved in 110 ml of piperidine/DMF 1:10 and the solution was stirred at room temperature for 1 hour. The mixture was evaporated and chromatographed over silica gel (methylene chloride/methanol 19:1, then 9:1). Yield: 1.8 g (72.5%) C30H31N5O2 (493.2) MS (FAB) 494 M + H+ 1.7 g (3.44 mmol) of the compound from Example 2 a were stirred with 1.4 g (3.61 mmol) of Fmoc-L-phenylalanine, 1.9 g (5.80 mmol) of TOTU and 1.0 ml of triethylamine in 150 ml of DMF at room temperature for 4 hours. The reaction mixture was evaporated and the residue was chromatographed over silica gel (ethyl acetate/n-heptane 4:1). Two fractions were obtained: 1 st fraction 1.28 g (43%) of non-polar diastereomer (Example 2 b/1) C54H50N6O5 (862.4) MS (FAB) 863.4 M + H+ 2nd fraction 0.82 g (28%) of polar diastereomer (Example 2 b/1) C54H50N6O5 (862.4) MS(FAB) 863.4 M + H+ 0.8 g (0.93 mmol) of the compound from Example 2 b/2 were dissolved in 33 ml of DMF/piperidine 10:1 and the solution was stirred at room temperature for 1 hour. After evaporation, the residue was chromatographed over silica gel (methylene chloride/methanol 19:1, then 9:1). Yield: 0.35 g (59%). C39H40N6O3 (640.3) MS (FAB) 641.3 M + H+ The examples of Table 2 were obtained analogously to Examples 1g and 2 a starting from Examples 1e and 1f. Example 95 1.6 g of the amine of the formula VI or VIII and 0.98 g of 12-nitrododecanoic acid were dissolved in 30 ml of dimethylformamide. 1,6 g of 0-((ethoxycarbonyl)cyanomethyleneamino)-N,N,N',N'- tetramethyluronium tetrafluoroborate (TOTU), 0.6 g of ethyl (hydroxyimino)-cyanoacetate and 1.6 ml of N-ethylmorpholine were added and the mixture was stirred at room temperature for about 2 hours. When the reaction had ended (TLC), the reaction mixture was extracted by stirring with 500 ml of water and 200 ml of methylene chloride and the organic phase was separated off, dried and concentrated in vacuo. After column chromatography (CC; Si02, ethyl acetate/n-heptane = 2:1), the amide was obtained as a viscous oil. Empirical formula: C37H45N504; (623.4) ; MS(FAB): 624.4 M+H+ 2.2 g of the amide were dissolved in 200 ml of ethanol and, after addition of a catalytic amount of Raney nickel (aqeuous suspension), hydrogenation was carried out in a duck-shaped shaking vessel under normal pressure at room temperature. The mixture was filtered off with suction over a clarifying layer and concentrated to give, after CC (Si02, methylene chloride/methanol/ammonia = 90:10:1) Example 95. Empirical formula: C37H47N502 ( 593.8) MS(FAB): 595 M+H+ 1.2 g of Example 96, 390 mg of China acid and 330 mg of N-hydroxy-benzotriazole were dissolved in 100 ml of tetrahydrofuran, and 500 mg of dicyclohexylcarbodiimide were added. The mixture was stirred at room temperature for 17 hours, filtered and concentrated. The residue was taken up in about 500 ml of ethyl acetate, extracted by shaking successively with NaHCC-3 solution, 2N citric acid, NaHC03 solution and water, dried and concentrated. After column filtration (ethyl acetate/methanol = 9:1), Example 3 was obtained, melting point 95°C. Empirical formula: C44H47N507 (768), MS(FAB): 768.4 M+H+ 593 mg of Example 96 and 265 mg of the abovementioned carboxylic acid were dissolved in 20 ml of DMF. 600 mg of TOTU, 300 mg of ethyl hydroxy-imino-cyanoacetate and 1 ml of N-ethylmorpholine were added and the mixture was stirred at room temperature for about 2 hours. When the reaction had ended (TLC), ethyl acetate was added and the mixture was washed in each case twice with water and NaHC03 solution, the organic phase was concentrated and the residue was purified by CC (Si02, ethyl acetate/methanol = 9;1). The amide Example 4 of melting point 105°C was obtained. Empirical formula: C52H56N803 (840,5); MS: 842 (M+H+). The following substances were prepared analogously to Example 4 from the amine Example 2 and the corresponding carboxylic acid: WE CLAIM: 1. A compound of the formula I, Z is -NH-^-C^-aJkyfHOO)-; -(C=OHC1-C16-alkylHC=0)-; -(C=0)-phenyi-(C=0)-; A', Az, A3, A4, Independently of one another are an amino acid radical, an amino acid radical which Is mono-or polysubstituted by amino acid-protective groups; E is -SOrR4, -CO-R4; R1 is phenyl, thiazolyl, oxazolyl.thlenyl, thiophenyl, furanyl, pyridyl, py rim Idyl, it being possible for the rings to be substituted up to 3 times by F, CI. Br, OH, CF3, N02, CN, OCF3, -(C1-Ce)alkyl, 0-(C^C6Hl^,S-(C^C8^al^,S0■{C1-Ce)-aJf(yl,SO^-(C1-Cfl^-aH^y(,(C1-CB)-alf!y^.(C3-C6)-cy-cioalkyl. COOH, COO(C1-Ce)alkyl, COO(C3-CB)cycloalkyl, CONH2, CONH{C1-C8)alkyl, CONK^-CgJalkyl];. CONH{C3-Ce)cycloalkyl, NH;, NH-CO-fq-CeValkyl, NH-CO-phenyl; R2 is H, OH, CHjOH, OMe; R3 Is H, F, methyl, OMe; R4 is -{Cj-C^-alkyl), -(C0-C16-alkylene)-R5, -(C=OMC0-C16-alkylene)-R5, -(C=O)-{C0-Cie-alkylene) -NH-R5, -(C1-Ca-alk6nylene)-R5, - R5 is -COO-R6, -{C=0)- Re, -(C1-Ce-alkylene)-R'T -{q-Ce-atkenyleneJ-R? , -(C^J-cycloalkyl, phe- nyl, naphthyl, thienyl, thiophenyl, furanyl, pyridyl, pyrimidyl, dihydropyrimldine-2,4-dion-6-yl, chromanyl, phthalimidoyl, thiazoiyl, it being possible for the rings to be substituted up to 3 times by F, CI. Br, OH, CF3. N02, CN, OCF3, -(C1-C„)-alkyl, O-^-Cet-alkyl, S^-Cel-alkyl, SO-^-CgJ-alkyl, S02-(C1-CB)-alkyl, {C1-C9)-atkyl, (C3-C6)-cycloalkyl. COOH, COO(C1-C6) alkyl. COO{C3-Ce)cycloalkyl, CONH2, CONHiq-Cgtelkyl, CON[(C1-C6)alkyl)2. CONH(C3-C6) cycloalkyt, NH2. NH-CO-(C1-C6)alkyl, NH-CO-phenyl, pyridyl; R6 Js H,-(C^CgJalkyl; R7 is H, -{C1-C7)-cycloalkyl, phenyl, naphthyl, thienyl, thiophenyl, furanyl, pyridyl, pyrimidyl, dihydro- pyrimldine-2,4-dlon-6-yl, chromanyl, phthalimidoyl, thiazolyl, It being passible for the rings to be substituted up to 3 times by F, CI, Br, OH, CF3, NO;, CN, OCF3, -(C1-C6)-alkyl, O-fC1-ChalkyI, S-fC^gJalkyl, SO-(C1-C6)-alkyl, SCy^-C^-alky!, (C1-C6)-alkyl, (C3-Ca)-cydoalkyl, COOH, COO(C1-Ce)alttyl, COO(c3-C8)cycloalkyl, CONH2, CONH{C1-Ce>alkyl, CONKCTCgJalkyl];,, CONH(C3-CB)cydoalkyl, NH2, NH-CO-(C1-C6^lkyl. NH-CO-phenyl; I, qT m, n, o, p Independently of one another are 0 or 1, where l+q+m+n+o+p is greater than or equal to 1; and pharmaceutical^ tolerated salts thereof. 2. A compound of the formula I as claimed in claim 1, wherein 2 is -NH-^-C^-alkylHC-O)-, -(COHC1-C^alkylHOoj-, -(C=O)-phenyl-(C=0)-; A1, A2, A3, A4 Independently of one- another are an amino acid radical, an amino acid radical which Is mono-or polysubstituted by amino acid-protective groups; E Is -S02-R4. -CO-R4; R1 is phenyl, thiazolyl, oxazolyl, thienyl, thiophenyl, furanyl, pyridyl, pyrimidyl, It being possible for the rings to be substituted up to 3 times by F, CI, Br, OH, CF3. NOz, CN, OCF3, -{C^gjalkyi, 0-(C1-CB)-alkyl, S-(C1-C8)-alkyl, SO-(C1-C6)-alkyl, SOj-fC^eJ-alkyl, (C1-C6)-alkyl, (C3-C6)-cy-cloalkyl, COOH, COO(C1-C6)alkyl, COO(C3-Ca)cycloalkyl. CONH2, CONH(C 1-Ce)alkyl, CONffCvCeJalkyl];, CONH(C3-C6)cycloalkyl, NH2, NH-CO-{C1-Ca)-alkyl. NH-CO-phenyl,; R^is H, OH, CH2OH, OMe; R3ls H, F, methyl, OMe; Ris -(Cs-C1B-alkyl), -(C0-C1B-alkylene)-R5, -(C=O)-(C0-C1s-alkylene)-R5, -{C=OHC0-C16-alkyJene) -NH-R5, ^1-Ca-alkenylene)-Rs, -(C1-Ce-alkynyl), -(C1-C4-alkylene)-S(0)o.2 -R5, -{C1-C4-alkyiene)-0-R5, -(C^-aikyleneJ-NH -R5; R5 is -COO-R8, -(C=0)- Re, -(d-Cff-alkylenaJ-R7, -{C1-C6-alkenylene)-R7 , -(C1-C7)-cycloalkyl, phe- nyl, naphthyl, thienyl, thiophenyl, furanyl, pyridyl, pyrimidyl, dihydropyrimidine-2,4-dion-e-yi, chromanyl, phthalimidoyl, thiazolyl, It being possible for the rings to be substituted up to 3 times by F, CI, Br, OH, CF3, NOj, CN, OCF3, -(C1-C8)-alkyl, 0-(C1-CB)alkyl, S-(C1-C6)-alky!, SO-fC^CeJ-alkyl, SOj-fC^eJ-alkyl, (^-Cs^alkyl. (C3-CB)-cycloalkyl. COOH, COO(C1-Ca) alkyl,COO(C3-Ce)cycloalkyl,CONH2,CONH(C1-Ca)all(yi,CON[(C1-C6)alkyll2-CONH{C3-C6)cy-doalkyl, NH2, NH-CO-(C1-C6)-alkyl, NH-CO-phenyl, pyridyl; R8is H.-tq-Cglalkyl; R7 is H, -{C1-C7)-cycloalkyl, phenyl, naphthyl, thienyl, thiophenyl, furanyl, pyridyl, pyrimidyl, dihydro- pyrimkJine-2,4-dion-6-yl, chromanyl, phthalimldoyi, thiazolyl, it being possible for the rings to be substituted up to 3 times by F, CI, Br, OH, CF3, N02, CN. OCF3, -(C1-Ce)-alkyll 0-{C1-CB)-alkyl, S-(C1-C6)alkyl, SOKC1-C6)-alkyl, SOr(C1-Ca)-alkvl, (d-C^alky!. (C3-CB)-cydoalkyf, COOH. COO^-CaJalkyl, COOfCj-Cgjcydoalkyl, CONH2, CONH^-C^alkyl. CONf(C1-Ca)alkyl]2. CONH(C3-CB)cydoalkyl, NH2, NH-CO-(C1-C6)alkyl, NH-CO-phenyt; lis Oor1; m, n are 0; o is 1; p is 0 or 1; qis 0or1; and pharmaceutical!y tolerated salts thereof. 3. A compound of the formula I as claimed In claim 1 or 2, wherein Z is -NH-(C1-C12-alkyl)-(C=0)-, -(C=OHC1-C12-alkyl)-(C=0)-, -(C=0)-phenyl- A1, A7, A3, A4 independently of one another are an amino acid radical, an amino acid radical which is mono-or polysubstltuted by amino acid-protective groups; E is -S02-R4. -CO-R4; R1 Is phenyl, thiaiolyl, oxazolyl, it being possible for the rings to be substituted up to 3 times by - R2is H.OH,CH2OH,OMe; R3is H, F, methyl. OMe; R is -(C5-C,6-alkyl), -(C0-C16-alkylene)-R5, -(C=OWC0-C1s-alkyiene)-R5, -(C=OMC0-C16-alkylene) -NH-R5. -(C1-C6-alkenylene)-R6p -(C1-Ca-alkynyl), -(C1-C4-alkylene)-S{O)0,2 -R5, -(C^C^-alkylBne}-0 -R5, -(C1-C4-alkylene)-NH -R5; R5 is -COO-R6, -(C=0)- Rs . -(Cl-C7)-cycloalkyl, phenyl, naphthyl, thienyl, thiophenyl, furanyl. pyridyl. pyrtmldyl, dlhydropyrlmidine-2,4-dion-6-yl, chromanyl, phthalimidoyl, thlazolyl, it being possible for the rings to be substituted up to twice by F, CI, Br, OH, CF3, NO;, CN, OCF3,- R6is H, -(C1-C6)afJtyl; l,m, nare 0; ois 1; p is 0 or 1; q is 0 or 1; and pharmaceutical^ tolerated salts thereof. 4- A pharmaceutical composition comprising one or more compounds as claimed in one or more of claims 1 to 3.

Full Text

Substituted 1,3-diaryl-2-pyrid-2-yl-3-(pyrid-2-ylamino)propanol derivatives, processes for their preparation, pharmaceuticals comprising these compounds and their use
The invention relates to substituted 1,3-diaryl-2-pyridin-2-yl-3-(pyridin-2-yiamino)propanol derivatives and pharmaceutical ly tolerated salts and physiologically functional derivatives thereof.
Several classes of active compounds for treatment of adiposity and disturbances in lipid metabolism have already been described:
- polymeric adsorbers, such as, for example, cholestyramine
- benzodiazepines (WO 93/16055)
- bile acid dimers and conjugates (EP 0 489 423)
- 4-amino-2-ureido-pyrimidine-5-carboxamides (EP 0 557 879)
The invention was based on the object of providing further compounds which display a therapeutically valuable hypolipidemic action.
The invention therefore relates to 1,3-diaryl-2-pyridin-2-yl-3-(pyridin-2-ylamino)propanol derivatives of the formula I,

in which
Zis -NH-(Ci-Cie-alkyl)-(C=0)-;
-(C=0)-(Ci-Ci6-alkyl)-(C=0)-; ./r.-rw.nHcLn\A.ir-rw- ■

12 3 4
A , A , A , A , independently of one another are an amino acid radical, an amino acid radical which is mono- or polysubstituted by amino acid-protective groups;
E is -S02-R4, -CO-R4;
R is phenyl, thiazolyl, oxazolyl, thienyl, thiophenyf, furanyl, pyridyl,
pyrimidyl, it being possible for the rings to be substituted up to
3 times by F, CI, Br, OH, CF3, N02, CN, OCF3, -(Ci-C6)-
alkyl, (XCt-CeJ-alkyl, S-(Ci-C6)-alkyl, SO-(Ci-C6)-alkyl,
S02-(Ci-C6)-alkyl, (Ci-C6)-alkyl, (C3-C6)-cycloalkyl, COOH,
COO(Ci-Ce)alkyl, COO(C3-C6)cycloalkyl, CONH2,
CONH(Ci-C6)alkyl, CON[(Ci-C6)alkyl]2, CONH(C3-
C6)cycloalkyl, NH2, NH-CO-(Ci-C6)-alkyl, NH-CO-phenyl;
R2is H, OH, CH2OH, OMe;
R3 is H, F, methyl, OMe;
R4 is -(Ci-Cie-alkyI), -(C0-Ci6-alkylene)-R5, -(C=O)-(C0-Ci6-
alkylene)-R5, -(C=O)-(C0-C16-alkylene)-NH-R5, -(Ci-C8-alkenylene)-R5, -(Ci-C8-alkynyl), -(Ci-C4-alkylene)-S(O)0 - 2 -R5, -{Ci-C4-alkylene)-0 -R5, -(Ci-C4-alkylene)-NH -R5;
R5is -COO-R6, -(C=0)- R6 , -(Ci-C6-alkylene)-R7, -(Ci-C6-
alkenylene)-R , {-(Ci-C7)-cycloalkyl, phenyl, naphthyl,
thienyl, thiophenyl, furanyl, pyridyl, pyrimidyl,
dihydropyrimidine-2,4-dion-6-yl, chromanyl, phthalimidoyl,
thiazolyl, it being possible for the rings to be substituted up to
3 times by F, CI, Br, OH, CF3, N02, CN, OCF3, -(Ci-C6)-
alkyl, 0-(Ci-C6)-alkyl, S-(Ci-C6)-alkyl, S0-(Ci-C6)-alkyl,
S02-(Ci-C6)-alkyl, (Ci-C6)-alkyl, (C3-C6)-cycloalkyl, COOH,
COO(Ci -C6)alkyl, COO(C3-C6)cycloalkyl, CONH2,
CONHfCrCelalkyl, CON[(Ci-C6)alkyl]2, CONH(C3-C6)cycloalkyl, NH2, NH-CO-(Ci-C6)-alkyl, NH-CO-phenyl, pyridyl;

R6 is H,-(Ci-C6)alkyl;
R is H, (-(C-|-C7)-cycloalkyl, phenyl, naphthyl, thienyl, thiophenyl,
furanyl, pyridyl, pyrimidyl, dihydropyrimidine-2,4-dion-6-yl, chromanyl, phthalimidoyl, thiazolyl, it being possible for the rings to be substituted up to 3 times by F, CI, Br, OH, CF3, N02, CN, OCF3, -(Ci-C6)-alkyl, 0-(Ci-C6)-alkyl, S- I, q, m, n, 0, p independently of one another are 0 or 1, where l+q+m+n+o+p is greater than or equal to 1;
and pharmaceutical^ tolerated salts and physiologically functional derivatives thereof.
Preferred compounds of the formula I are those in which one or more radical(s) has or have the following meaning:
Z -NH-(Ci-Ci6-alkyl)-(C=0)-,
- A , A , A , A , independently of one another, an amino acid radical, an amino acid radical which is mono- or polysubstituted by amino acid-protective groups;
E -SO2-R4, -CO-R4;
R phenyl, thiazolyl, oxazolyl, thienyl, thiophenyl, furanyl, pyridyl,
pyrimidyl, it being possible for the rings to be substituted up to
3 times by F, CI, Br, OH, CF3, N02, CN, OCF3, -(Ci-C6)-
alkyl, 0-(Ci-C6)-alkyl, S-(Ci-Ce)-alkyl, S0-(Ci-C6)-alkyl,
S02-(Ci-C6)-alkyl, (Ci-C6)-alkyl, (C3-C6)-cycloalkyl, COOH,
COO(d-C6)alkyl, COO(C3-C6)cycloalkyl, CONH2,

CONH(Ci-C6)alkyl, CON[(Ci-C6)alkyl]2, CONH(C3-C6)-cycloalkyl, NH2, NH-CO-(d-C6)-alkyl, NH-CO-phenyl,;
R2 H, OH, CH2OH, OMe;
R3 H, F, methyl, OMe;
R4 -(Ci-Cie-alkyI), - alkylene)-R5, -(C=O)-(C0-C16-a!kylene)-NH-R5, -(Ci-C8-alkenylene)-R5, -{Ci-C8-alkynyl), -(Ci-C4-alkylene)-S(0)o - 2 -R5, -(d-C4-alkylene)-0 -R5, -(Ci-C4-alkylene)-NH -R5;
R5 -COO-R6, -(C=0)- R6 , -(Ci-C6-alkylene)-R7, -(Ci-C6-
alkenylene)-R , -(Ci-C7)-cycloalkyl, phenyl, naphthyl, thienyl,
thiophenyl, furanyl, pyridyl, pyrimidyl, dihydropyrimidine-
2,4-dion-6-yl, chromanyl, phthalimidoyl, thiazolyl, it being
possible for the rings to be substituted up to 3 times by F, CI,
Br, OH, CF3, N02, CN, OCF3, -(Ci-C6)-alkyl, 0-(Ci-C6)-
alkyl, S-(Ci-C6)-alkyl, SO-(Ci-C6)-alkyl, S02-(Ci-C6)-alkyl,
(Ci-C6)-alkyl, (C3-C6)-cycloalkyl, COOH, COO(Ci-C6)alkyl,
COO(C3-C6)cycloalkyl, CONH2, CONH(C-|-C6)alkyl,
CON[(Ci-C6)aikyl]2, CONH(C3-C6)cycloalkyl, NH2, NH-CO-(Ci-C6)-alkyl, NH-CO-phenyl, pyridyl;
R6 H,-(d-C^alkyl;
R H, (-(Ci-C7)-cycloalkyl, phenyl, naphthyl, thienyl, thiophenyl,
furanyl, pyridyl, pyrimidyl, dihydropyrimidine-2,4-dion-6-yl, chromanyl, phthalimidoyl, thiazolyl, it being possible for the rings to be substituted up to 3 times by F, CI, Br, OH, CF3, N02, CN, OCF3, -(d-CeJ-alkyl, 0-(CrC6)-alkyl, S-(Ci-C6)-alkyl, SO-td-CeJ-alky], S02-{Ci-C6)-alkyl, (d-C6)-alkyl, (C3-C6)-cycloalkyl, COOH, COO(d-C6)alkyl, COO(C3-C6)cycloalkyl, CONH2, CONH(d-C6)alkyl, CON[(CT C6)alkyl]2, CONH(C3-C6)cycloalkyl, NH2, NH-CO-(Ci-C6)-alkyl, NH-CO-phenyl;
I 0 or 1;

m, n 0;
o 1;
p 0 or 1;
q 0or1;
and pharmaceutical^ tolerated salts and physiologically functional
derivatives thereof.
Particularly preferred compounds of the formula I are those in which one or more radical(s) has or have the following meaning:
2 -NH-(Ci-Ci2-alkyl)-(C=0)-,
-(C=OHCi-Ci2-alkyl)-(C=0)-, -(C=0)-phenyl-(C=0)-;
12 3 4
A , A , A , A , independently of one another, an amino acid radical, an amino acid radical which is mono- or polysubstituted by amino acid-protective groups;
E -S02-R4, -C0-R4;
R phenyl, thiazolyl, oxazolyl, it being possible for the rings to be
substituted up to 3 times by -(Ci-CeValkyl;
R2 H, OH, CH2OH, OMe;
R3 H, F, methyl, OMe;
R4 -(Ci-Cie-alkyI). -(C0-Ci6-alkyiene)-R5, -(C=0)-(Co-Ci6-
alkylene)-R5, -(C=OHC0-Ci6-alkylene)-NH-R5, -(Ci-C8-alkenylene)-R , -(C-i-Cs-alkynyl), -(Ci-C4-alkylene)-S(0)o - 2 -R5, -(Ci-C4-alkylene)-0 -R5, -(Ci-C4-alkylene)-NH -R5;
R5 -COO-R6, - thienyl, thiophenyl, furanyl, pyridyl, pyrimidyl, dihydropyrimidine-2,4-dion-6-yl, chromanyl, phthalimidoyl, thiazolyl, it being possible for the rings to be substituted up to twice by F, CI, Br, OH, CF3, N02, CN, OCF3, -(Ci-C6)-alkyl, 0-(Ci -C6)-alkyl, COOH, COO(Ci -C6)alkyl, CONH2,

CONH(CrC6)alkyl, CON[(Ci-C6)alkyl]2, CONH(C3-
C6)cycloalkyl, NH2, NH-CO-(Ci-C6)-alkyl, NH-CO-phenyl, pyridyl;
R6 H.-(Ci-Ce)alkyl;
I, m, n 0;
o 1;
p 0 or 1;
q 0 or 1;
and pharmaceutically tolerated salts thereof.
The term alkyl is understood as meaning straight-chain or branched hydrocarbon chains.
By the term amino acids or amino acid radicals is meant, for example, the stereoisomeric forms, i.e. D- or L-forms, of the following compounds:
alanine glycine proline
cysteine histidine glutamine
aspartic acid isoleucine arginine
glutamic acid lysine serine
phenylalanine leucine threonine
tryptophan methionine valine
tyrosine asparagine
2-aminoadipic acid 2-aminoisobutyric acid
3-aminoadipic acid 3-aminoisobutyric acid
beta-alanine 2-aminopimelic acid
2-aminobutyric acid 2,4-diaminobutyric acid
4-aminobutyric acid desmosine
piperidic acid 2,2-diaminopimelic acid
6-aminocaproic acid 2,3-diaminopropionic acid
2-aminoheptanoic acid N-ethylglycine
2-(2-thienyl)-glycine 3-(2-thienyl)-alanine
penicillamine sarcosine
N-ethylasparagine N-methylisoleucine

hydroxylysine 6-N-methyllysine
allo-hydroxy lysine N-methylvaline
3-hydroxyproline norvaline
4-hydroxyproline norleucine
isodesmosine ornithine
allo-isoleucine 3-(2-naphthyl)alanine
azaglycine N-cyclohexylglycine
2,4-diaminobutyric acid
The abbreviated spelling of the amino acids is in accordance with the generally customary spelling (cf. Schroder, Liibke, The Peptides, Volume I, New York 1965, pages XXII-XXIII; Houben-Weyl, Methoden der Organischen Chemie [Methods of organic chemistry], Volume XV/1 and 2, Stuttgart 1974). The amino acid pGlu represents pyroglutamyl, Nal represents 3-(2-naphthyl)alanine, Azagly-Nhfe represents a compound of the formula NH2-NH-CONH2 and D-Asp represents the D-form of aspartic acid. Peptides are acid amides in their chemical nature and dissociate into amino acids on hydrolysis.
The invention furthermore relates to processes for the preparation of compounds of the formula I which comprise the following reaction equations (Equation 1 to 6).
The compounds of the formula I according to the invention are prepared starting from compounds of the formulae VI or VII in stages from the free amino group or by coupling of segments by the general methods of peptide chemistry (Houben-Weyl, Methoden der Organischen Chemie, Volume 15/1,2). The peptide couplings can be carried out, for example, with TOTU (for the literature see: G. Breipohl, W. Kbnig EP 0460446; W. Kbnig, G. Breipohl, P. Pokorny, M. Birkner in E. Giralt and D. Andreu (Eds.) Peptides 1990, Escom, Leyden, 1991, 143-145) by the method of mixed anhydrides, via active esters, azides or by the carbodiimide method, in particular with the addition of substances which accelerate the reaction and prevent racemization, such as, for example, 1-hydroxybenzotriazole, N-hydroxysuccinimide, 3-hydroxy-4-oxo-3,4-dihydro-1,2,3-benzotriazine, N-hydroxy-5-norbornene-2,3-dicarboximide, and furthermore using active derivatives of 1-hydroxybenzotriazole or anhydrides of phosphoric, phosphonic and phosphinic acids, at a reaction temperature of between

-10°C and the boiling point of the solvent, preferably between -5°C and 40°C.
Suitable solvents for this are dimethylformamide, dimethylacetamide, N-methylpyrrolidone or dimethyl sulfoxide. If the solubility of the components allows, solvents such as methylene chloride, chloroform or tetrahydrofuran or mixtures of the solvents mentioned can also be employed. The methods mentioned are described, for example, in Meinhofer-Gross: "The Peptides" Academic Press, Volume I, (1979).
If necessary to prevent side reactions or for the synthesis of specific peptides, the functional groups in the side chain of amino acids are additionally protected by suitable protective groups (see, for example, T.W. Greene, "Protective Groups in Organic Synthesis"), Arg(BOC)2, Arg(Tos), Arg(Mts), Arg(Mtr), Arg(PMV), Asp(OBzl), Asp(OBut), Cys(4-MeBzl), Cys(Acm), Cys(SBut), Glu(OBzl), Glu(OBut), His(Tos), His(Fmoc), His(Dnp), His(Trt), Lys(CI-Z), Lys(Boc), Met(O), Ser(Bzl), Ser(But), Thr(Bzl), Thr(But), Trp(Mts), Trp(CHO), Tyr(Br-Z), Tyr(Bzl) or Tyr(But) primarily being employed.
The benzyloxycarbonyl (Z) radical, which can be split off by catalytic hydrogenation, the 2-(3,5-dimethyloxyphenyl)propyl(2)oxycarbonyl (Ddz) or trityl (Trt) radical, which can be split off by weak acids, and the 9-fluorenyl-methyloxycarbonyl (Fmoc) radical, which can be split off by secondary amines, are preferably used as the amino-protective groups. The SH group of cysteine can be blocked by a number of protective groups. The trityl (Trt) radical and the S-tert-butyl (StBu) radical are preferred here. The trityl radical can be split off by iodine oxidation with formation of the cystine compounds, or by reducing acid cleavage to give the cysteine compounds (Uebigs Ann. Chem. 1979, 227-247).
On the other hand, the S-tert-butyl radical is best split off reductively with tributylphosphine (Aust. J. Chem. 19 (1966) 2355-2360). OH and COOH functions in the side chains are best protected by the tert-butyl (tBu) radical, which can be split off under acid conditions (see also: Meienhofer-Gross: "The Peptides", Volume 3).
The compounds of the formulae VI and VII are prepared as follows:

Compounds of type IV are obtained by reacting o-, m- or p-substituted imines of type II with the ketone III. The reaction can be carried out, for example, by mixing the two compounds in bulk, without a solvent, and subsequently heating the mixture, or in a suitable solvent, such as ethanol, tetrahydrofuran (THF), toluene, diglyme or tetradecane, at temperatures of 20°Cto150°C.
The keto compounds of type IV are reduced with NaBhU or another suitable reducing agent in a suitable solvent, such as, for example, methanol, THF or THF/water, at temperatures between -30°C and + 40°C to give hydroxy compounds of type V. Two isomer mixtures (racemates) are usually obtained as the main products in the reduction. The different racemates can be separated from one another by fractional crystallization or by silica gel chromatography. The nitro group in compounds of type V

can be reduced by known processes, such as, for example, catalytic hydrogenation with Pd or Pd-on-charcoal and H2 in methanol.
The racemic compounds of type VI thus obtained can be separated further into their enantiomers. The racemate splitting of VI into enantiomers of type VII can be carried out by chromatography over chiral column material or by processes which are known from the literature, using optically active auxiliary reagents (cf. J. Org. Chem. 44, 1979, 4891).
Preparation of the compounds of the formula I according to the invention starting from compounds of type VI or VII.

Compounds of the formula VI or VII are reacted with derivatives of aminoalkanecarboxylic acids. Peptide coupling processes are employed here. The aminoalkanecarboxylic acids, for example glycine, IB-alanine or co-ami no undecanoic acid, are protected with Fmoc groups, and corresponding nitro- or azidocarboxylic acids, for example, can also be used. After the protective group has been split off in a second step, or

correspondingly after reduction of the azido or nitro group, compounds of the formula VIII are obtained.
Compounds of the formulae VI, VII or VIII can be reacted with amino-protected, for example Fmoc-protected amino acids by peptide coupling processes, and the side chains can be protected with suitable orthogonal protective groups or unprotected. After the coupling reaction, the protective group of the amino function is split off, in the case of Fmoc, for example, with piperidine in DMF. The compounds of type IX obtained therefrom can be reacted in one to three further reaction sequences - amino acid coupling, splitting off of the amino-protective group - to give compounds of the formula X. The protective groups of the side chains of the amino acids A to A , which number up to four, can be split off individually after each reaction sequence or together after all the coupling reactions, or all or some of them can also remain on the compounds X according to the invention.
Process B

The free amino functions of compounds of the formulae VI, VII, VIII, IX or X are reacted with carboxylic acids, also by customary amide formation methods. Functional groups of the starting compounds which can lead to side reactions must be present in protected form, and can be split off after the reaction with the carboxylic acid, if necessary. The compounds according to the invention of type XI are obtained therefrom.

Analogously to process B, the sulfonamide derivatives XII are obtained from the compounds of the formulae VI to IX. For the preparation, the amino functions of the starting compounds can be reacted, for example, with sulfonic acid chlorides in the presence of an auxiliary base in a suitable solvent.

Compounds of type XIII can be obtained by reaction of dicarboxylic acid monoalkyl esters with compounds of type VI or VII, X representing an alkyl or a phenyl radical, in accordance with the claims. The reaction is carried out by customary peptide coupling processes. The alkyl ester function is then hydrolyzed to the carboxylic acid in order to obtain compounds of the formula XIV. The compounds XIV can also be obtained directly from the amines of type VI or VII by reaction with dicarboxylic acid anhydrides, for example succinic anhydride, in the presence of a base. If the carboxylic

acid function of the compounds XIV is reacted with amino acid alkyl esters which a protective group may carry in the side chain, compounds of the formula XV are obtained. The compounds of the formula XVI are in turn prepared therefrom by hydrolysis of the alkyl ester function. Processes A - D can also be modified in the same sense such that the compounds according to the reaction may be prepared by reactions on a solid phase. This is shown in process E by a general example.
Process E

The compound of the formula V is coupled to a modified polystyrene resin. For this, the carboxyl group of Carboxy-Tentagel (Rapp, Tubingen) is reacted with the OH function of the compound VI by esterification methods, for example DCC or DMAP. The nitro group of the compound XVII thus obtained is converted into the amino function by suitable methods, for example SuCfe reduction processes. On derivative XVIII, which is bonded to the solid phase, the side chain (E)7-(A )p-(A )0-(A )n-(A )m-(Z)e is built up to the desired length analogously to the peptide coupling processes

already described. In the last step, the compounds of the formula I according to the invention are split off from the solid phase by hydrolysis of the ester group under basic conditions.
The radicals described as protective groups of amino acid side chains in the processes described can remain in the compounds according to the invention or can be split off by known methods (see T.W. Greene "Protective Groups in Organic Synthesis").
The compounds of the formula I thus obtained can optionally be converted into their pharmaceutical^ tolerated salt or physiologically functional derivative.
Because of their higher solubility in water compared with the starting or base compounds, pharmaceutically tolerated salts are particularly suitable for medical uses. These salts must have a pharmaceutically tolerated anion or cation. Suitable pharmaceutically tolerated acid addition salts of the compounds according to the invention are salts of inorganic acids, such as hydrochloric acid or hydrobromic, phosphoric, metaphosphoric, nitric, sulfonic and sulfuric acid, and of organic acids, such as, for example, acetic acid or benzenesulfonic, benzoic, citric, ethanesulfonic, fumaric, gluconic, glycolic, isethionic, lactic, lactobionic, maleic, malic, methanesulfonic, succinic, p-toluenesulfonic, tartaric and trifluoroacetic acid. For medical purposes, the chlorine salt is particularly preferably used. Suitable pharmaceutically tolerated basic salts are ammonium salts, alkali metal salts (such as sodium and potassium salts) and alkaline earth metal salts (such as magnesium and calcium salts).
Salts with an anion which is not pharmaceutically tolerated are also included in the scope of the invention as beneficial intermediate products for the preparation or purification of pharmaceutically tolerated salts and/or for use in non-therapeutic, for example in vitro applications.
The term "physiologically functional derivative" used here designates any physiologically tolerated derivative of a compound according to the invention, for example an ester, which, when administered to a mammal, such as, for example, humans, is capable of forming (directly or indirectly), such a compound or an active metabolite.

Prodrugs of the compounds according to the invention are another aspect of this invention. Such prodrugs can be metabolized in vivo to give a compound according to the invention. These prodrugs may or may not be active themselves.
The compounds according to the invention can also exist in various polymorphous forms, for example as amorphous and crystalline polymorphous forms. All the polymorphous forms of the compounds according to the invention are included in the scope of the invention and are a further aspect of the invention.
All references to "compound(s) according to formula (I)" in the following text relate to compound(s) of the formula (I) as described above and their salts, solvates and physiologically functional derivatives as described herein.
The amount of a compound according to formula (I) which is necessary to achieve the desired biological effect depends on a number of factors, for example the specific compound chosen, the intended use, the mode of administration and the clinical condition of the patient. In general, the daily dose is in the range from 0.3 mg to 100 mg, {typically from 3 mg to 50 mg) per day per kilogram of bodyweight, for example 3-10 mg/kg/day. An intravenous dose can be, for example, in the range from 0.3 mg to 1.0 mg/kg, which can suitably be administered as an infusion of 10 ng to 100 ng per kilogram per minute. Suitable infusion solutions for this purpose can comprise, for example, from 0.1 ng to 10 mg, typically from 1 ng to 10 mg per milliliter. Individual doses can comprise, for example, from 1 mg to 10 g of the active compound. Thus, ampoules for injections can contain, for example, from 1 mg to 100 mg, and individual dose formulations for oral administration, such as, for example, tablets or capsules, can contain, for example, from 1.0 to 1000 mg, typically from 10 to 600 mg. In the case of pharmaceutical^ tolerated salts, the abovementioned weight data relate to the weight of the benzothiazepine ion derived from the salt. For prophylaxis or treatment of the abovementioned conditions, the compounds according to formula (I) can be used themselves as the compound, but they are preferably present together with a tolerated excipient in the form of a pharmaceutical composition. The excipient must of course be tolerated in the sense that it is compatible with the other constituents of the composition and does not harm the health of the patient. The excipient can be a solid or a liquid or

both and is preferably formulated with the compound as an individual dose, for example as a tablet, which can comprise from 0.05% to 95% by weight of the active compound. Further pharmaceutically active substances can also be present, including further compounds according to formula (I). The pharmaceutical compositions according to the invention can be prepared by one of the known pharmaceutical methods, which substantially comprise mixing the constituents with pharmacologically tolerated excipients and/or auxiliaries.
Pharmaceutical compositions according to the invention are those which are suitable for oral, rectal, topical, peroral (for example sublingual) and parenteral (for example subcutaneous, intramuscular, intradermal or intravenous) administration, although the most suitable mode of administration in each individual case depends on the nature and severity of the condition to be treated and on the nature of the particular compound according to formula (I) used. Coated formulations and coated sustained-release formulations are also included in the scope of the invention. Formulations which are resistant to acid and gastric juice are preferred. Suitable coatings which are resistant to gastric juice include cellulose acetate phthalate, polyvinyl acetate phthalate, hydroxyp ropy I methyl-cellulose phthalate and anionic polymers of methacrylic acid and methyl methacrylate.
Suitable pharmaceutical compounds for oral administration can be present in separate units, such as, for example, capsules, cachets, sucking tablets or tablets, each of which comprises a certain amount of the compound according to formula (I); as powders or granules; as a solution or suspension in an aqueous or non-aqueous liquid; or as an oil-in-water or water-in-oil emulsion. As already mentioned, these compositions can be prepared by any suitable pharmaceutical method which comprises a step in which the active compound and the excipient (which can consist of one or more additional constituents) are brought into contact. The compositions are in general prepared by uniform and homogeneous mixing of the active compound with a liquid and/or finely divided solid excipient, after which the product is shaped, if necessary. Thus, for example, a tablet can be prepared by pressing or shaping a powder or granules of the compound, optionally with one or more additional constituents. Pressed tablets can be prepared by tableting the compound in a free-flowing form, such as, for example, a powder or granules, optionally mixed with a binder, lubricant,

inert diluent and/or one (or more) surface-active/dispersing agents, in a suitable machine. Shaped tablets can be prepared by shaping the pulverulent compound, which has been moistened with an inert liquid diluent, in a suitable machine.
Pharmaceutical compositions which are suitable for peroral (sublingual) administration include sucking tablets which comprise a compound according to formula (I) with a flavoring substance, usually sucrose, and gum arabic or tragacanth, and pastilles, which comprise the compound in an inert base, such as gelatin and glycerol, or sucrose and gum arabic.
Suitable pharmaceutical compositions for parenteral administration include, preferably, sterile aqueous formulatlions of a compound according to formula (I), which are preferably isotonic with the blood of the intended recipient. These formulations are preferably administered intravenously, although the administration can also take place subcutaneously, intramuscularly or intradermally as an injection. These formulations can preferably be prepared by mixing the compound with water and rendering the resulting solution sterile and isotonic with blood. Injectable compositions according to the invention in general comprise 0.1 to 5% by weight of the active compound.
Suitable pharmaceutical compositions for rectal administration are preferably in the form of individual-dose suppositories. These can be prepared by mixing a compound according to formula (I) with one or more conventional solid excipients, for example cacao butter, and introducing the mixture formed into a mold.
Suitable pharmaceutical compositions for topical use on the skin are preferably in the form of an ointment, cream, lotion, paste, spray, aerosol or oil. Vaseline, lanolin, polyethylene glycols, alcohols and combinations of two or more of these substances can be used as excipients. The active compound is in general present in a concentration of 0.1 to 15% by weight of the composition, for example 0.5 to 2%.
Transdermal administration is also possible. Suitable pharmaceutical compositions for transdermal applications can be in the form of individual 3atches which are suitable for long-term close contact with the epidermis of the patient. Such patches suitably comprise the active compound in an

optionally buffered aqueous solution, dissolved and/or dispersed in an adhesion promoter or dispersed in a polymer. A suitable active compound concentration is about 1% to 35%, preferably about 3% to 15%. As a particular possibility, the active compound can be released by electric transportation or iontophoresis, as described, for example, in Pharmaceutical Research, 2(6): 318 (1986).
The invention furthermore relates both to isomer mixtures of the formula I and to the pure enantiomers of the formula I.
The compounds of the formula I and pharmaceutical^ tolerated salts and physiologically functional derivatives thereof are ideal pharmaceuticals for treatment of disturbances in lipid metabolism, in particular hyperlipidemia. The compounds of the formula I are also suitable for influencing the serum cholesterol level and for prevention and treatment of arteriosclerotic symptoms. The following findings demonstrate the pharmacological activity of the compounds according to the invention.
Biological testing of the compounds according to the invention was carried out by determining the inhibition of [ H]-taurocholate uptake in brush border membrane vesicles of the ileum of rabbits. The inhibition test was carried out as follows:
1. Preparation of brush border membrane vesicles from the ileum of
rabbits
Brush border membrane vesicles from the intestinal cells of the small
2+
intestine were prepared by the so-called Mg precipitation method. Male
New Zealand rabbits (2 to 2.5 kg bodyweight) were sacrificed by
® intravenous injection of 0.5 ml T61 , an aqueous solution of 2.5 mg
tetracaine HCI, 100 m embutramide and 25 mg mebezonium iodide. The small intestine was removed and rinsed with ice-cold physiological saline solution. The terminal 7/10 of the small intestine (measured in the oral-rectal direction, i.e. the terminal ileum, which contains the active Na -dependent bile acid transportation system) was used for preparation of the brush border membrane vesicles. The intestines were frozen in plastic bags under nitrogen at -80°C. For preparation of the membrane vesicles, the frozen intestines were thawed at 30°C in a water-bath. The mucosa was scraped off and suspended in 60 ml of ice-cold 12 mM Tris/HCI buffer

2+
addition of Mg and precipitate, with the exception of the brush border membranes. After centrifugation at 3000 x g (5000 rpm, SS-34 rotor) for 15 minutes, the precipitate was discarded and the supernatant, which contains the brush border membranes, was centrifuged at 48000 x g (20000 rpm, SS-34 rotor) for 30 minutes. The supernatant was discarded, and the precipitate was rehomogenized in 60 ml of 12 mM Tris/HCI buffer (pH 7.1)/60mM mannitol, 5 mM EGTA with a Potter Elvejhem homogenizer (Braun, Melsungen, 900 rpm, 10 strokes). After addition of 0.1 ml of 1 M MgCl2 solution and an incubation time of 15 minutes at 0°C, centrifugation was again carried out at 3000 x g for 15 minutes. The supernatant was then centrifuged again at 48000 x g (20000 rpm, SS-34 rotor) for 30 minutes. The precipitate was taken up in 30 ml of 10 mM Tris/Hepes buffer (pH 7.4)/300 mM mannitol and resuspended homogeneously by 20 strokes in a Potter Elvejhem homogenizer at 1000 rpm. After centrifugation at 48000 x g (20000 rpm, SS-34 rotor) for 30 minutes, the precipitate was taken up in 0.5 to 2 ml of Tris/Hepes buffer (pH 7.4)/280 mM mannitol (final concentration 20 mg/ml) and resuspended with the aid of a Tuberculin syringe with a 27-gauge needle. The vesicles were either used for transportation investigations directly after preparation or stored at -196°C in 4 mg portions in liquid nitrogen.
2. Inhibition of the Na+-dependent [ H]taurocholate uptake in brush border membrane vesicles of the ileum
The uptake of substrates in the brush border membrane vesicles described above was determined by means of the so-called membrane filtration technique. 10^1 of the vesicle suspension (100 /jg of protein) were pipetted as drops onto the wall of a polystyrene incubation tube (11 x 70 mm) which contained the incubation medium with the corresponding ligands (90 //I). The incubation medium comprised 0.75 /J\ = 0.75 juCi [ H(G)]-taurocholate (specific activity: 2.1 Ci/mmol)/0.5 /J\ of 10 mM taurocholate/8.75/W of

sodium transportation buffer (10 mM Tris/Hepes (pH 7.4)/100mM mannitol/100mM NaCI) (Na-T-P) or 8.75//I of potassium transportation buffer (10 mM Tris/Hepes (pH 7.4)/100 mM mannitol/100 mM KCI) (K-T-P) and 80 fj\ of the inhibitor solution in question, dissolved in Na-T buffer or K-T-buffer, depending on the experiment. The incubation medium was filtered through a polyvinylidenefluoride membrane filter (SYHV LO 4NS, 0.45 fjm, 4 mm 0, Millipore, Eschborn, Germany). The transportation measurement was started by mixing the vesicles with the incubation medium. The concentration of taurocholate in the incubation batch was 50 pM. After the desired incubation time (usually 1 minute), the transportation was stopped by addition of 1 ml of ice-cold stopping solution (10 mM Tris/Hepes (pH 7.4)/150mM KCI). The mixture formed was immediately filtered with suction under a vacuum of 25 to 35 mbar over a membrane filter of cellulose nitrate (ME 25, 0.45 ym, 25 mm diameter, Schleicher & Schuell, Dassell, Germany). The filter was rinsed with 5 ml of ice-cold stopping solution.
To measure the uptake of the radioactively labeled taurocholate, the membrane filter was dissolved with 4 ml of the scintillator Quickszint 361 (Zinsser Analytik GmbH, Frankfurt, Germany) and the radioactivity was measured by liquid scintillation measurement in a TriCarb 2500 measuring apparatus (Canberra Packard GmbH, Frankfurt, Germany). The values measured were obtained as dpm (decompositions per minute) after calibration of the apparatus with the aid of standard samples and after correction for any chemiluminescence present.
The control values were each determined in Na-T-P and K-T-P. The difference between the uptake in Na-T-P and K-T-P gave the Na -dependent transportation content. That concentration of inhibitor at which the Na -dependent transporation content was inhibited by 50% - based on the control - is designated the IC50 Na+.
The pharmacological data comprise a test series in which the interaction of the compounds according to the invention with the intestinal bile acid transportation system in the terminal small intestine was investigated. The results are summarized in Table 1.
3 Table 1 shows measurement values of the inhibition of the [ H]-
taurocholate uptake in brush border membrane vesicles of the ileum of

rabbits. The quotients of the ICsoNa values of the reference substance as taurochenodeoxycholate (TCDC) and of the particular test substance are stated.

366 ml of 15% strength n-butyllithium in n-hexane were added dropwise to 50 g (0.54 mol) of picoline in 770 ml of tetrahydrofuran at -55°C. The mixture was warmed to room temperature and cooled again to -55°C. 77 g of N,N-dimethylbenzamide (0.52 mol) in 570 ml of tetrahydrofuran were slowly added dropwise, and the mixture was then warmed to room temperature and stirred for a further hour. After addition of 550 ml of 1N hydrochloric acid, the mixture was extracted with ethyl acetate (3x) and the organic phases were dried with MgS04 and evaporated. Distillation of the residue gave 47.5 g (47%) of the product. Boiling point 134-136°C/0.28mbar.

20.0 g (0.13 mol) of o-nitrobenzaldehyde, 12.5 g (0.13 mol) of
2-aminopyridine and 0.3 g of p-toluenesulfonic acid were heated under
reflux in 150 ml of toluene for 2.5 hours, using a water separator. The
solution was cooled and the precipitate formed was filtered off with suction
and dried.
Yield: 18.1 g (60%) of product
Melting point: 93-95°C
C12H9N3O2 (227) MS (FAB) 228 M + H+

12.0 g (61 mmol) of the ketone from Example 1 a and 15.0 g (66 mmol) of
the imine from Example 1 b were heated on a steam bath for 45 minutes.
The reaction mixture was dissolved in ethanol, with heating. After cooling,
the precipitate was filtered off with suction and recrystallized from ethanol.
Yield: 11.8 g (46%) of product
C25H20N4O3 (424.2) MS (FAB) 425 M + H+

8.0 g (18.8 mmol) of the keto compound from Example 1 c w re dissolved in 300 ml of tetrahydrofuran/water 10:1, 4.67 g of sodium bore lydride were added and the mixture was stirred at room temperature for ! hours. The solution was then evaporated, 100 ml of 2N hydrochloric acic were added to the residue and the mixture was heated on a steam bath ur til everything had dissolved. After cooling, the mixture was rendered basic v\ th 4N NaOH solution and extracted with ethyl acetate (2x). The organic ihases were dried with MgS04 and evaporated. The residue was chromato iraphed over silica gel (heptane/ethyl acetate 1:1). Two racemic comf ounds were obtained as the product.

1 st fraction: 3.9 g (48%) of non-polar racemate (Example 1 d/1)
C25H22N4O3 (426.2) MS (FAB) 427 M + H+
2nd fraction: 2.5 g (31%) of polar racemate (Example 1 d/2)
C25H22N4O3 (426.2) MS (FAB) 427 M + H+

2.5 g (5.86 mmol) of the non-polar racemate from Example 1 d/1 were
dissolved in 300 ml of methanol, about 20 mg of Pd/C 10% were added
and hydrogenation was carried out at room temperature under an H2
atmosphere. The catalyst was filtered off and the solution was evaporated.
The residue was chromatographed over silica gel (n-heptane/ethyl acetate
7:13).
Yield: 1.9 g (82%) of product
C25H24N4O (396.22) MS (FAB) 397 M + H+

100 mg of the racemic compound from Example 1 e was separated into the enantiomers by preparative HPLC. The separation was carried out over a CSP-Chiralpak column (Daicel, Dusseldorf) with n-hexane/ethanol 4:1.

40 mg of the (-)-enantiomer (Example 1 f/1) were obtained as the 1st fraction and 40 mg of the (+)-enantiomer (Example 1 f/2) were obtained as the 2nd fraction.

4.0 g (10.1 mmol) of the amino compound from Example 1e (non-polar
racemate), 4.85 g (10.3 mmol) of N-Fmoc-D-l_ys(BOC)OH, 4.0 g
(12.2 mmol) of TOTU and 2.7 ml of triethylamine were dissolved in 300 ml
of dimethylformamide and the mixture was stirred at room temperature for
2 hours. The reaction mixture was poured onto water and extracted with
ethyl acetate (2 x). The organic phases were dried (MgS04) and
evaporated. The residue was dissolved in 150 ml of dimethyl-
formamide/piperidine 2:1, for splitting off the Fmoc group, and the solution
was stirred at room temperature for 1 hour. It was poured onto water and
extracted with ethyl acetate (3 x). The organic phases were dried (MgS04)
and evaporated. Chromatography over silica gel (methylene
chloride/methanol 9:1) gave 4.0 g (63.5%) of the product
C36H44N6O4 (624.3) MS (FAB) 625 M + H+

4.74 g (43%) of the product were obtained from 8.0 g of the compound
from Example 1 g (12.8 mmol) and 6.4 g (13.7 mmol) of N-Fmoc-D-
Lys(BOC)OH by the process described under 1 g.
C47H64N8O7 (852.5) MS (FAB) 853.5 M + H+

2.5 g (6.31 mmol) of the amino compound from Example 1 e (non-polar racemate), 2.2 g (6.52 mmol) of Fmoc-L-proline, 2.5 g (7.62 mmol) of TOTU and 1.7 ml of triethylamine were dissolved in 100 ml of dimethyl-formamide and the solution was stirred at room temperature for 3 hours. The reaction mixture was evaporated to half, water was added and the mixture was extracted with ethyl acetate (3 x). The organic phases were dried over MgS04 and evaporated. After chromatography over silica gel (ethyl acetate/n-heptane 7:3), 3.85 g (85%) of product were obtained.
This Fmoc-protected intermediate product (3.6 g) was dissolved in 110 ml
of piperidine/DMF 1:10 and the solution was stirred at room temperature for
1 hour. The mixture was evaporated and chromatographed over silica gel
(methylene chloride/methanol 19:1, then 9:1).
Yield: 1.8 g (72.5%)
C30H31N5O2 (493.2) MS (FAB) 494 M + H+

1.7 g (3.44 mmol) of the compound from Example 2 a were stirred with
1.4 g (3.61 mmol) of Fmoc-L-phenylalanine, 1.9 g (5.80 mmol) of TOTU
and 1.0 ml of triethylamine in 150 ml of DMF at room temperature for
4 hours. The reaction mixture was evaporated and the residue was
chromatographed over silica gel (ethyl acetate/n-heptane 4:1). Two
fractions were obtained:
1 st fraction 1.28 g (43%) of non-polar diastereomer (Example 2 b/1)
C54H50N6O5 (862.4) MS (FAB) 863.4 M + H+
2nd fraction 0.82 g (28%) of polar diastereomer (Example 2 b/1)
C54H50N6O5 (862.4) MS(FAB) 863.4 M + H+

0.8 g (0.93 mmol) of the compound from Example 2 b/2 were dissolved in
33 ml of DMF/piperidine 10:1 and the solution was stirred at room
temperature for 1 hour. After evaporation, the residue was
chromatographed over silica gel (methylene chloride/methanol 19:1, then
9:1).
Yield: 0.35 g (59%).
C39H40N6O3 (640.3) MS (FAB) 641.3 M + H+

The examples of Table 2 were obtained analogously to Examples 1g and 2 a starting from Examples 1e and 1f.

Example 95
1.6 g of the amine of the formula VI or VIII and 0.98 g of
12-nitrododecanoic acid were dissolved in 30 ml of dimethylformamide.
1,6 g of 0-((ethoxycarbonyl)cyanomethyleneamino)-N,N,N',N'-
tetramethyluronium tetrafluoroborate (TOTU), 0.6 g of ethyl (hydroxyimino)-cyanoacetate and 1.6 ml of N-ethylmorpholine were added and the mixture was stirred at room temperature for about 2 hours. When the reaction had ended (TLC), the reaction mixture was extracted by stirring with 500 ml of water and 200 ml of methylene chloride and the organic phase was separated off, dried and concentrated in vacuo. After column chromatography (CC; Si02, ethyl acetate/n-heptane = 2:1), the amide was

obtained as a viscous oil. Empirical formula: C37H45N504; (623.4) ; MS(FAB): 624.4 M+H+

2.2 g of the amide were dissolved in 200 ml of ethanol and, after addition of a catalytic amount of Raney nickel (aqeuous suspension), hydrogenation was carried out in a duck-shaped shaking vessel under normal pressure at room temperature. The mixture was filtered off with suction over a clarifying layer and concentrated to give, after CC (Si02, methylene chloride/methanol/ammonia = 90:10:1) Example 95. Empirical formula: C37H47N502 ( 593.8) MS(FAB): 595 M+H+

1.2 g of Example 96, 390 mg of China acid and 330 mg of N-hydroxy-benzotriazole were dissolved in 100 ml of tetrahydrofuran, and 500 mg of dicyclohexylcarbodiimide were added. The mixture was stirred at room temperature for 17 hours, filtered and concentrated. The residue was taken up in about 500 ml of ethyl acetate, extracted by shaking successively with NaHCC-3 solution, 2N citric acid, NaHC03 solution and water, dried and concentrated. After column filtration (ethyl acetate/methanol = 9:1), Example 3 was obtained, melting point 95°C. Empirical formula: C44H47N507 (768), MS(FAB): 768.4 M+H+

593 mg of Example 96 and 265 mg of the abovementioned carboxylic acid were dissolved in 20 ml of DMF. 600 mg of TOTU, 300 mg of ethyl hydroxy-imino-cyanoacetate and 1 ml of N-ethylmorpholine were added and the mixture was stirred at room temperature for about 2 hours. When the reaction had ended (TLC), ethyl acetate was added and the mixture was washed in each case twice with water and NaHC03 solution, the organic phase was concentrated and the residue was purified by CC (Si02, ethyl acetate/methanol = 9;1). The amide Example 4 of melting point 105°C was obtained. Empirical formula: C52H56N803 (840,5); MS: 842 (M+H+).
The following substances were prepared analogously to Example 4 from the amine Example 2 and the corresponding carboxylic acid:

WE CLAIM:
1. A compound of the formula I,

Z is -NH-^-C^-aJkyfHOO)-;
-(C=OHC1-C16-alkylHC=0)-; -(C=0)-phenyi-(C=0)-;
A', Az, A3, A4, Independently of one another are an amino acid radical, an amino acid radical which Is mono-or polysubstituted by amino acid-protective groups;
E is -SOrR4, -CO-R4;
R1 is phenyl, thiazolyl, oxazolyl.thlenyl, thiophenyl, furanyl, pyridyl, py rim Idyl, it being possible for the
rings to be substituted up to 3 times by F, CI. Br, OH, CF3, N02, CN, OCF3, -(C1-Ce)alkyl, 0-(C^C6Hl^,S-(C^C8^al^,S0■{C1-Ce)-aJf(yl,SO^-(C1-Cfl^-aH^y(,(C1-CB)-alf!y^.(C3-C6)-cy-cioalkyl. COOH, COO(C1-Ce)alkyl, COO(C3-CB)cycloalkyl, CONH2, CONH{C1-C8)alkyl, CONK^-CgJalkyl];. CONH{C3-Ce)cycloalkyl, NH;, NH-CO-fq-CeValkyl, NH-CO-phenyl;
R2 is H, OH, CHjOH, OMe;
R3 Is H, F, methyl, OMe;
R4 is -{Cj-C^-alkyl), -(C0-C16-alkylene)-R5, -(C=OMC0-C16-alkylene)-R5, -(C=O)-{C0-Cie-alkylene)
-NH-R5, -(C1-Ca-alk6nylene)-R5, - R5 is -COO-R6, -{C=0)- Re, -(C1-Ce-alkylene)-R'T -{q-Ce-atkenyleneJ-R? , -(C^J-cycloalkyl, phe-
nyl, naphthyl, thienyl, thiophenyl, furanyl, pyridyl, pyrimidyl, dihydropyrimldine-2,4-dion-6-yl, chromanyl, phthalimidoyl, thiazoiyl, it being possible for the rings to be substituted up to 3 times by F, CI. Br, OH, CF3. N02, CN, OCF3, -(C1-C„)-alkyl, O-^-Cet-alkyl, S^-Cel-alkyl, SO-^-CgJ-alkyl, S02-(C1-CB)-alkyl, {C1-C9)-atkyl, (C3-C6)-cycloalkyl. COOH, COO(C1-C6) alkyl. COO{C3-Ce)cycloalkyl, CONH2, CONHiq-Cgtelkyl, CON[(C1-C6)alkyl)2. CONH(C3-C6) cycloalkyt, NH2. NH-CO-(C1-C6)alkyl, NH-CO-phenyl, pyridyl;

R6 Js H,-(C^CgJalkyl;
R7 is H, -{C1-C7)-cycloalkyl, phenyl, naphthyl, thienyl, thiophenyl, furanyl, pyridyl, pyrimidyl, dihydro-
pyrimldine-2,4-dlon-6-yl, chromanyl, phthalimidoyl, thiazolyl, It being passible for the rings to be substituted up to 3 times by F, CI, Br, OH, CF3, NO;, CN, OCF3, -(C1-C6)-alkyl, O-fC1-ChalkyI, S-fC^gJalkyl, SO-(C1-C6)-alkyl, SCy^-C^-alky!, (C1-C6)-alkyl, (C3-Ca)-cydoalkyl, COOH, COO(C1-Ce)alttyl, COO(c3-C8)cycloalkyl, CONH2, CONH{C1-Ce>alkyl, CONKCTCgJalkyl];,, CONH(C3-CB)cydoalkyl, NH2, NH-CO-(C1-C6^lkyl. NH-CO-phenyl;
I, qT m, n, o, p Independently of one another are 0 or 1, where l+q+m+n+o+p is greater than or equal to 1;
and pharmaceutical^ tolerated salts thereof.
2. A compound of the formula I as claimed in claim 1, wherein
2 is -NH-^-C^-alkylHC-O)-,
-(COHC1-C^alkylHOoj-, -(C=O)-phenyl-(C=0)-;
A1, A2, A3, A4 Independently of one- another are an amino acid radical, an amino acid radical which Is mono-or polysubstituted by amino acid-protective groups;
E Is -S02-R4. -CO-R4;
R1 is phenyl, thiazolyl, oxazolyl, thienyl, thiophenyl, furanyl, pyridyl, pyrimidyl, It being possible for the
rings to be substituted up to 3 times by F, CI, Br, OH, CF3. NOz, CN, OCF3, -{C^gjalkyi, 0-(C1-CB)-alkyl, S-(C1-C8)-alkyl, SO-(C1-C6)-alkyl, SOj-fC^eJ-alkyl, (C1-C6)-alkyl, (C3-C6)-cy-cloalkyl, COOH, COO(C1-C6)alkyl, COO(C3-Ca)cycloalkyl. CONH2, CONH(C 1-Ce)alkyl, CONffCvCeJalkyl];, CONH(C3-C6)cycloalkyl, NH2, NH-CO-{C1-Ca)-alkyl. NH-CO-phenyl,;
R^is H, OH, CH2OH, OMe;
R3ls H, F, methyl, OMe;
R*is -(Cs-C1B-alkyl), -(C0-C1B-alkylene)-R5, -(C=O)-(C0-C1s-alkylene)-R5, -{C=OHC0-C16-alkyJene)
-NH-R5, ^1-Ca-alkenylene)-Rs, -(C1-Ce-alkynyl), -(C1-C4-alkylene)-S(0)o.2 -R5, -{C1-C4-alkyiene)-0-R5, -(C^-aikyleneJ-NH -R5;
R5 is -COO-R8, -(C=0)- Re, -(d-Cff-alkylenaJ-R7, -{C1-C6-alkenylene)-R7 , -(C1-C7)-cycloalkyl, phe-
nyl, naphthyl, thienyl, thiophenyl, furanyl, pyridyl, pyrimidyl, dihydropyrimidine-2,4-dion-e-yi, chromanyl, phthalimidoyl, thiazolyl, It being possible for the rings to be substituted up to 3 times by F, CI, Br, OH, CF3, NOj, CN, OCF3, -(C1-C8)-alkyl, 0-(C1-CB)alkyl, S-(C1-C6)-alky!,
SO-fC^CeJ-alkyl, SOj-fC^eJ-alkyl, (^-Cs^alkyl. (C3-CB)-cycloalkyl. COOH, COO(C1-Ca) alkyl,COO(C3-Ce)cycloalkyl,CONH2,CONH(C1-Ca)all(yi,CON[(C1-C6)alkyll2-CONH{C3-C6)cy-doalkyl, NH2, NH-CO-(C1-C6)-alkyl, NH-CO-phenyl, pyridyl;
R8is H.-tq-Cglalkyl;
R7 is H, -{C1-C7)-cycloalkyl, phenyl, naphthyl, thienyl, thiophenyl, furanyl, pyridyl, pyrimidyl, dihydro-
pyrimkJine-2,4-dion-6-yl, chromanyl, phthalimldoyi, thiazolyl, it being possible for the rings to be substituted up to 3 times by F, CI, Br, OH, CF3, N02, CN. OCF3, -(C1-Ce)-alkyll 0-{C1-CB)-alkyl, S-(C1-C6)alkyl, SOKC1-C6)-alkyl, SOr(C1-Ca)-alkvl, (d-C^alky!. (C3-CB)-cydoalkyf, COOH. COO^-CaJalkyl, COOfCj-Cgjcydoalkyl, CONH2, CONH^-C^alkyl. CONf(C1-Ca)alkyl]2. CONH(C3-CB)cydoalkyl, NH2, NH-CO-(C1-C6)alkyl, NH-CO-phenyt;

lis Oor1;
m, n are 0;
o is 1;
p is 0 or 1;
qis 0or1;
and pharmaceutical!y tolerated salts thereof.
3. A compound of the formula I as claimed In claim 1 or 2, wherein
Z is -NH-(C1-C12-alkyl)-(C=0)-,
-(C=OHC1-C12-alkyl)-(C=0)-, -(C=0)-phenyl- A1, A7, A3, A4 independently of one another are an amino acid radical, an amino acid radical which is mono-or polysubstltuted by amino acid-protective groups;
E is -S02-R4. -CO-R4;
R1 Is phenyl, thiaiolyl, oxazolyl, it being possible for the rings to be substituted up to 3 times by
- R2is H.OH,CH2OH,OMe;
R3is H, F, methyl. OMe;
R* is -(C5-C,6-alkyl), -(C0-C16-alkylene)-R5, -(C=OWC0-C1s-alkyiene)-R5, -(C=OMC0-C16-alkylene)
-NH-R5. -(C1-C6-alkenylene)-R6p -(C1-Ca-alkynyl), -(C1-C4-alkylene)-S{O)0,2 -R5, -(C^C^-alkylBne}-0 -R5, -(C1-C4-alkylene)-NH -R5;
R5 is -COO-R6, -(C=0)- Rs . -(Cl-C7)-cycloalkyl, phenyl, naphthyl, thienyl, thiophenyl, furanyl. pyridyl.
pyrtmldyl, dlhydropyrlmidine-2,4-dion-6-yl, chromanyl, phthalimidoyl, thlazolyl, it being possible for the rings to be substituted up to twice by F, CI, Br, OH, CF3, NO;, CN, OCF3,- R6is H, -(C1-C6)afJtyl;
l,m, nare 0;
ois 1;
p is 0 or 1;
q is 0 or 1;
and pharmaceutical^ tolerated salts thereof.

4- A pharmaceutical composition comprising one or more compounds as claimed in one or more of claims 1 to 3.

Documents:

in-pct-2001-0459-che abstract-duplicate.pdf

in-pct-2001-0459-che abstract.pdf

in-pct-2001-0459-che claims-duplicate.pdf

in-pct-2001-0459-che claims.pdf

in-pct-2001-0459-che correspondence-others.pdf

in-pct-2001-0459-che correspondence-po.pdf

in-pct-2001-0459-che description (complete)-duplicate.pdf

in-pct-2001-0459-che description (complete).pdf

in-pct-2001-0459-che form-1.pdf

in-pct-2001-0459-che form-13.pdf

in-pct-2001-0459-che form-19.pdf

in-pct-2001-0459-che form-26.pdf

in-pct-2001-0459-che form-3.pdf

in-pct-2001-0459-che form-5.pdf

in-pct-2001-0459-che others.pdf

in-pct-2001-0459-che pct.pdf

in-pct-2001-0459-che petition.pdf

« Previous Patent

Next Patent »

Patent Number

223550

Indian Patent Application Number

IN/PCT/2001/459/CHE

PG Journal Number

47/2008

Publication Date

21-Nov-2008

Grant Date

12-Sep-2008

Date of Filing

02-Apr-2001

Name of Patentee

SANOFI-AVENTIS DEUTSCHLAND GMBH

Applicant Address

BRUNINGSTRASSE 50, D-65929 FRANKFURT AM MAIN,

Inventors:

#	Inventor's Name	Inventor's Address
1	KIRSCH, REINHARD	STEINTORWALL 17, 38100 BRANNSCHWEIG,
2	ENHSEN,ALFONS	BIRKENWEG 4, 64572 BUTTELBORN,
3	GLOMBIK, HEINER	AM LOTZENWALD 42, 65719 HOFHEIM,
4	KRAMER, WERNER	HENRY-MOISAND STRASSE 19, 55130 MAINZ-LAUBENHEIM,
5	FALK, EUGEN	VOLKLINGERWEG 15, 60529 FRANKFURT AM MAIN,

PCT International Classification Number

C07D213/74

PCT International Application Number

PCT/EP99/06933

PCT International Filing date

1999-09-18

PCT Conventions:

#	PCT Application Number	Date of Convention	Priority Country
1	19845406.6	1998-10-02	Germany